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resumo 
 
 
O presente relatório de estágio tem como objetivo descrever, em 
detalhe, o meu estágio curricular de dez meses na Unidade de 
Farmacologia Clínica do Instituto de Medicina Molecular.  
Este estágio insere-se nas atividades curriculares do segundo ano do 
Mestrado em Biomedicina Farmacêutica da Universidade de Aveiro.  
O principal foco deste estágio curricular foi a coordenação de ensaios 
clínicos, na área da neurologia, num centro de investigação clínica. No 
entanto, este foi um estágio muito rico e diversificado e portanto, eu 
também tive a oportunidade de desenvolver atividades em outras áreas 
do sector do medicamento, nomeadamente em farmacovigilância, 
escrita científica, gestão de dados e monitorização.  
Este estágio representou o meu primeiro contacto com o mundo do 
trabalho e permitiu a criação de uma ponte entre o mundo académico e 
o mundo do trabalho. Este permitiu-me colocar em prática o 
conhecimento adquirido durante a Universidade, compreender como 
várias áreas do sector do medicamento funcionam na prática, 
complementar o meu conhecimento teórico e melhorar as minhas soft 
skills. 
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abstract 
 
The present internship report aims to describe, in detail, my curricular 
training of ten months at the Unidade de Farmacologia Clínica of the 
Instituto de Medicina Molecular.  
This training is part of the curricular activities of the second year of the 
Masters in Pharmaceutical Biomedicine of the University of Aveiro. 
The main focus of this curricular training was the coordination of clinical 
trials, in the area of neurology, in a clinical research centre. However, 
this was a very rich and diversified training and therefore, I also had the 
opportunity of develop activities in other areas of the drug sector, 
namely pharmacovigilance, medical writing, data management and 
monitoring.  
This training represented my first contact with the working world and 
enabled the establishment of a bridge between the academic world and 
the working world. It allowed me to put in practice the knowledge 
acquired during the University, to understand how various areas of the 
drug sector work in the practice, to complement my theoretical 
knowledge and to improve my soft skills. 
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1. Introduction 
This document is an internship report which aims to describe my curricular training of ten months 
carried out at the Unidade de Farmacologia Clínica (UFC; Clinical Pharmacology Unit) of the 
Instituto de Medicina Molecular (IMM).  
The curricular training was carried out during the second year of my Master’s Course in 
Pharmaceutical Biomedicine, provided by the University of Aveiro, and was undertaken in order 
to complete this course and acquire professional experience in clinical research, 
pharmacovigilance, medical writing and data management. It was supervised by Professor Doctor 
Joaquim Ferreira and Professor Doctor Alexandra Queirós. 
The UFC is led by Professor Joaquim Ferreira and comprises six sub-units. During my training, I 
only developed activities in three of them: the Centro de Investigação Clínica (CIC; Clinical 
Research Centre); the sub-unidade de Bioestatística e Metodologia (SBM; Biostatistics and 
Methodological sub-unit) and the Unidade Regional de Farmacovigilância de Lisboa e Vale do Tejo 
(URFLVT; Regional Pharmacovigilance Unit of Lisboa and Vale do Tejo). 
My curricular training started on 2nd September 2014 and lasted until 3rd July 2015. The training 
consisted of a rotating approach. I started my activities at the CIC and stayed there during two 
months, then I went to the SBM and developed activities there during two months and, 
subsequently, I went to the URFLV where I stayed during two months too. The last four months of 
my training were spent at the CIC. The rotating scheme of the training is represented in the Figure 
1. 
 2014 2015 
 Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul 
CIC               
SBM              
URFLVT              
Figure 1 – Rotation Scheme of the Curricular Training 
Throughout this report I am going to use the term “clinical studies” to define clinical trials (CT) 
and observational studies (OS). The term “drug” is going to be used too as “medicine” and 
“medicinal product”. 
1.1. Objectives 
When I started the curricular training, in September 2014, I defined various objectives that 
reflected my expectations regarding the training and what I hoped to learn with it. The primary 
objectives were those that I necessarily had to achieve by the end of the training. The secondary 
objectives could be achieved or not by the end of the training. 
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1.1.1. Primary Objectives 
 Acquire qualifications and skills in the coordinating of clinical studies; 
 Perform all the activities that are within the competence of a Study Coordinator (SC); 
 Understand how a Regional Pharmacovigilance Unit works, particularly the URFLVT, and 
perform the daily activities undertaken at the Unit; 
 Apply the previously acquired academic background in a practical context and 
complement it; 
 Acquire practical/professional experience in the drug sector and identify my areas of 
interest in this sector or related with the clinical research area; 
 Improve my teamwork and communication skills and my capacity of interpersonal 
relationship. 
1.1.2. Secondary Objectives 
 Write a scientific paper related to the area of clinical research; 
 Improve my writing skills by carrying out activities of medical writing; 
 Understand how a Biostatistics and Methodological Unit works and acquire knowledge in 
this area by participating in the projects ongoing at the Unit; 
1.2. Report Structure 
This internship report is divided in seven main sections: Introduction – Chapter 1, Vision of Host 
Institution – Chapter 2, State of the Art – Chapter 3, On the Job Training – Chapter 4, Discussion – 
Chapter 5, Conclusion – Chapter 6 and References.  
The first chapter, Introduction, describes the scope of this internship report, presents an overview 
of my curricular training and identifies the objectives that I hope to achieve at the end of the 
training. 
The second one, Vision of Host Institution, presents an overview of the host institution, 
highlighting particularly the organization, constitution, objectives and activities developed by the 
UFC.  
The State of the Art, the third chapter, provides some background on various topics of the drug 
sector that are essential to understand the scope of this report and the activities developed 
during the training. 
The fourth chapter, On the Job Training, is the main chapter of this report. It describes all the 
activities that I carried out during my curricular training.  
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The fifth chapter, Discussion, presents a discussion about the ten months of training, highlighting 
the lessons learned during this time frame. The next chapter, Conclusion, sums up the final 
thoughts about the training. 
The last section, References, lists all the references that I used to support this report.  
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2. Vision of Host Institution  
The IMM was officially the host institution of my curricular training. More concretely, my 
curricular training took place at one of the 34 research labs of the IMM – the UFC. However, the 
UFC is not located in the building of the IMM but at the Centro Hospitalar Lisboa Norte, E.P.E. – 
Hospital Santa Maria (North Lisbon Hospital Centre, E.P.E – Santa Maria Hospital).  
This section aims to present an overview of the host institution, highlighting the research lab 
where I developed my activities.  
2.1. Instituto de Medicina Molecular  
The IMM is a private and non-profit association created in December 2002. It is located on the 
campus of the Faculdade de Medicina da Universidade de Lisboa (Faculty of Medicine of the 
University of Lisbon) (1). 
“The mission of the Instituto de Medicina Molecular (IMM) is to foster basic, clinical and 
translational biomedical research with the aim of contributing to a better understanding of 
disease mechanisms, developing novel predictive tests, improving diagnostics tools and 
developing new therapeutic approaches” (1, p.5).  
The IMM is part of the consortium entitled Centro Académico de Medicina de Lisboa (CAML; 
Lisbon Medical Academic Centre) that comprises also the Faculdade de Medicina da Universidade 
de Lisboa and the Centro Hospitalar Lisboa Norte, E.P.E. – Hospital Santa Maria. The three 
institutions share the same University Campus (2).  
2.2. Unidade de Farmacologia Clínica  
The UFC was officially created on the 1st July 2013 and is one of the 34 research labs of the IMM. 
Currently comprises six sub-units: the CIC, the URFLVT, the SBM, the sub-unidade de Avaliação de 
Medicamentos e Revisões Sistemáticas (Drug Evaluation and Systematic Reviews sub-unit), the 
Outcomes sub-unit and the Pharmaco Magnetic Resonance Imaging sub-unit (1).  
The main mission of the UFC is to contribute to the development of effective and safe therapeutic 
interventions through the establishment of optimized methodologies for the design, conduction, 
analysis and report of CT. The focus of the Unit is mainly on novel, early phase proof-of-principle 
clinical studies and new methodological and trial designs but the scope extends throughout the 
clinical development spectrum (1).  
The UFC is located on the 3th floor of the Centro Hospitalar Lisboa Norte, E.P.E. – Hospital Santa 
Maria. However, the UFC operates in a physical space entitled Laboratório de Farmacologia Clínica 
e Terapêutica (Laboratory of Clinical Pharmacology and Therapeutics) which belongs to the 
Faculdade de Medicina da Universidade de Lisboa. The only sub-unit of the UFC which does not 
operate in this physical space is the CIC, which operates in a different floor of the hospital. 
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A description of the sub-units where I develop activities is presented below. Regarding the other 
three sub-units, I only provide a brief description since I did not develop any activity there and 
therefore I do not have much knowledge about these sub-units. 
The sub-unit of Avaliação de Medicamentos e Revisões Sistemáticas comprises the Movement 
Disorders Cochrane Collaboration Review Group, which has expertise in conducting systematic 
reviews and related CT methodology issues (2).  
The Outcomes sub-unit is focused on the study of measurement instruments, including 
biomarkers and patient-reported outcomes in drug evaluation (2).  
The Pharmaco Magnetic Resonance Imaging sub-unit aims to detect micro-structural, functional 
and biochemical alterations in the central nervous system through the application of 
neuroimaging techniques (1).  
2.3. Centro de Investigação Clínica  
The clinical research centres, also known as sites, are a critical piece in the clinical development 
process (3). They are the entities responsible for conducting clinical studies, represent the 
physical space where the clinical studies are performed and are fitted with adequate human and 
material resources (3,4). Its ultimate purpose is to produce clean and reproducible clinical data in 
a timely and safe manner. The clinical research centres generate these clinical data by applying 
the study protocols on human subjects that they recruit. Through their activities, clinical research 
centres play a major role in moving investigational products through the clinical development 
phases on their way to regulatory submissions and ultimately, to market (3).  
Clinical studies are becoming more complex and including more procedures per subject, therefore 
it is crucial that the team at the clinical research centre is aware of what it takes to perform good-
quality clinical research in a timely, ethical and responsible way (3).  
The CIC was established in 1999 and is located on the 6th floor of the Neurology Department of 
the Centro Hospitalar Lisboa Norte, E.P.E. – Hospital Santa Maria. Although the CIC uses the 
physical space of the hospital, it does not belong to the hospital. The CIC currently belongs to the 
UFC, being a sub-unit of it. 
The centre has all the required conditions and equipment to conduct high quality clinical research. 
It has a meeting room where is possible to conduct all the necessary meetings and which is used 
by the study monitors who visit the centre to perform its monitoring activities. There is also 
another office room available to the SC. These two rooms together have enough space to archive 
almost all the documentation and laboratory material of the studies ongoing at the centre. The 
centre has also a consultation room to evaluate the patients and a room to collect biologic 
samples from the patients. Regarding equipment, both the meeting room and the office room 
have computers available with restricted access internet. The consultation room has all the 
medical calibrated material required to the assessments of the studies (e.g. 
sphygmomanometers, electrocardiographs, thermometers and scales). The CIC owns a calibrated 
centrifuge with temperature control to process patient samples.  
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In the CIC are conducted CT and OS in the field of neurology encompassing different diseases, 
namely: Parkinson’s Disease (PD), Huntington’s Disease (HD), Dystonia, Alzheimer’s Disease, 
Multiple Sclerosis, Epilepsy, etc. The majority of the studies conducted until now at the CIC had as 
therapeutic indication the PD (38 CT; 4 OS) and Multiple Sclerosis (15 CT; 23 OS). The CIC also 
conducted a great number of studies in other diseases namely: Alzheimer’s disease (16 CT), 
Epilepsy (13 CT; 1 OS); Familial Amyloid Polyneuropathy (FAP) (8 CT; 1 OS) and HD (4 CT; 1 OS). 
The Figure 2 illustrates all the clinical studies conducted at CIC since 1999 until 2015 distributed 
by therapeutic indication. 
 
 
Figure 2 – Number of Clinical Studies Conducted at CIC by Therapeutic Indication (1999-2015) 
(SIAHS – Syndrome of Inappropriate Antidiuretic Hormone Secretion) 
 
Figure 3 illustrates the total number of CT conducted at CIC distributed by phases since 1999 until 
2015. The majority of the CT conducted at CIC was of phase III (69 CT) and of phase II (16 CT). 
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Figure 3 – Clinical Trials Conducted at CIC by Phase (1999-2015) 
 
At the end of my training there were 22 CT and 10 OS on-going. 
The information presented above resulted from a search done by me at the CIC. My search was 
based on questions to the team and in the consultation of an internal database with all the clinical 
studies conducted at the CIC since 1999 until 2015. 
The CIC counts on a team of professionals qualified by education, training and experience. The 
team is highly motivated and willing to dispense time in the conduct of clinical studies. This is a 
great asset to the centre and the secret to being considered a centre of excellence. 
The centre is comprised of a multidisciplinary team of health professionals which includes: SC, 
principal investigators (PI) and sub-investigators, a laboratory technician, nurses, pharmacists and 
psychologists.  
The SC is usually considered the key element in the day-to-day activities of clinical research. The 
role played by the SC is essential to conduct CT with high quality and in a timely way. The 
responsibilities of a SC may include the following (3,5): 
 participation in trial budget preparation; 
 attend to investigator meetings; 
 provide support in recruitment  activities; 
 data entry in Case Report Forms (CRF) and query resolution; 
 archive and maintain the study files and records; 
 transmission of study data (e.g., transmission of electrocardiogram (ECG) through 
telephone network); 
1 
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 scheduling of patient visits and other procedures of the CT (e.g., some exams required by 
trial protocol); 
 instructing the trial participants; 
 coordinate with the pharmacist the preparation/dispense of the experimental 
medication; 
 meeting with PI and study monitors; 
 processing and shipping of biological samples to external laboratories; 
 close out the CT. 
The PI is the physician who is responsible for the conduct of a CT. The PI major responsibilities are 
first ensuring safety of trial participants; conducting the trial according to its protocol, the Good 
Clinical Practices (GCP) and applicable legislation and collaborating with the sponsor’s team 
members (6). The PI is also responsible for the recruitment, enrollment, medical follow-up and 
withdrawal (if necessary) of trial participants, obtainment of the informed consent, prescription of 
the experimental medication, report of adverse events and serious adverse events and lastly 
delegation of trial tasks. The PI is always responsible for all trial activity and for all personnel 
performance, so he/she should choose their sub-investigators and coordinators carefully (7).  
The sub-investigator is any member of the CT team designated and supervised by the investigator 
to perform critical trial-related procedures and/or to make important trial-related decisions (8).  
The laboratory technician and study nurses are responsible for collecting biological samples. The 
study nurses can also give support in the administration of the experimental medication (e.g., 
when the experimental medication is administered through an infusion or injection). 
The pharmacists are responsible for receiving, storing, dispensing and for the accounting of the 
experimental medication according to trial protocol. 
The psychologists are essential in the neurology CT, since they administer several scales required 
by trials protocols to the trial participants and their caregivers (e.g., Mini Mental State 
Examination, Columbia Suicide Severity Rating Scale, etc).  
2.4. Unidade Regional de Farmacovigilância de Lisboa e Vale do Tejo  
The URFLVT is one of the four Regional Pharmacovigilance Units of the Sistema Nacional de 
Farmacovigilância (SNF; Portuguese Pharmacovigilance System) and covers the population 
encompassed by the Health Regional Administration of Lisboa and Vale do Tejo Region. The main 
purpose of the URFLVT is to receive, validate, classify, process and proceed to the causality 
assessment of spontaneous reports of adverse drug reactions (ADR) that occur in the area 
covered by the Unit, and lastly report them to Autoridade Nacional do Medicamento e Produtos 
de Saúde I.P (INFARMED, National Authority of Medicines and Health Products, IP).  
The staff of the sub-unit consists of a physician which acts as director of the Unit and clinical 
coordinator; one pharmacist which acts as quality manager and pharmacist operating; one 
pharmacist which acts as pharmacist operating and pharmacist coordinator and one 
administrative assistant. 
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The SNF oversee the safety of the drugs commercialized in the national market, evaluating 
potential problems related with ADR and implementing safety measures whenever necessary (9).  
In Portugal, the SNF was created in 1992. It was first established in a centralized manner, but it 
was realized quickly that its geographic decentralization, through the creation of various Regional 
Pharmacovigilance Units, would allow a positive proximity of the system to the health 
professionals and the involvement of the universities (10).  
Currently, the SNF is comprised of the Direção de Gestão do Risco de Medicamentos (Medicine 
Risk Management Direction) of INFARMED, which coordinates the SNF, and by four Regional 
Pharmacovigilance Units: the Unidade Regional de Farmacovigilância do Norte (Northern Regional 
Pharmacovigilance Unit), the Unidade Regional de Farmacovigilância do Centro (Centre Regional 
Pharmacovigilance Unit), the Unidade Regional de Farmacovigilância de Lisboa e Vale do Tejo and 
the Unidade Regional de Farmacovigilâcia do Sul (Southern Regional Pharmacovigilance Unit) (9).  
These Regional Pharmacovigilance Units cover the entire mainland Portugal and are responsible 
for assuring the proper collection, processing and evaluation of spontaneous reports of ADR and 
for promoting the continuous disclosure of the SNF and of the spontaneous reporting among 
potential reporters (health professionals, patients, students, etc.). Additionally, the Regional Units 
also carry out some pharmaco-epidemiological studies in the area of drug safety (10).  
The Regional Pharmacovigilance Units are entities with technical and administrative autonomy 
and are headquartered in the various regions, usually in university institutions and/or research 
institutions in health. These carry out their activity within the defined legal framework and in 
close collaboration with the INFARMED, entity with which celebrate collaboration protocols or 
contracts for provision of services (11,12).  
The Figure 4 shows the evolution and maturation of the SNF since their creation in 1992 until 
2014. At the first years of existence of the SNF there was a high rate of underreporting. Over the 
years the reporting rate has been increasing reaching a total of 4618 ADR spontaneous reports in 
2014, a trend that shows that the efforts of the Regional Pharmacovigilance Units to promote the 
SNF among health professionals were worth it (13). The graphic also shows the effect of the new 
pharmacovigilance legislation regarding the report of ADR by users. Since 2012 the report of ADR 
by users has been increasing and is expected to continue to increase over the next years.  
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Figure 4 – Number of ADR Reports Received by the SNF by Reporter (1992-2014) (14)  
2.5. Sub-Unidade de Bioestatística e Metodologia  
This sub-unit plays activities of clinical data management; data quality control; biostatistics; 
medical writing and submission of scientific articles for publication in scientific journals; and 
development and submission of applications for scientific projects. 
The sub-unit provides statistical support to all research projects, mainly related with design and 
analysis of CT and systematic reviews. Regarding the methodological support, the sub-unit aims to 
support in the design, conduct, analysis and reporting of clinical research studies and to optimize 
study design and feasibility (2).  
The staff of the sub-unit consists of statisticians, data managers, project managers and physicians.  
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3. State of the Art 
This section presents an overview of the drug development process focusing in the clinical 
development; the problems of the current research and development (R&D) model and new 
trends in the R&D of new drug products; the current status of the clinical research in Portugal; the 
Portuguese and European regulatory framework in the clinical research area as well as an 
overview of the pharmacovigilance including its role and history, the new European 
pharmacovigilance legislation and how medicines are supervised in Portugal.  
3.1. Drug Development 
The discovery of new medicines has been an important part of transforming many diseases over 
the years (15). The pharmaceutical industry has contributed to significant enhancements in 
patient well-being. Nowadays, the European citizens can expect to live up to 30 years longer than 
a century ago and with better quality of life.  However, some diseases remain as major hurdles, 
namely Alzheimer’s Disease, Multiple Sclerosis and orphan diseases (16).  
Drug development is a stepwise process which includes drug discovery and laboratory 
development, preclinical studies, clinical development and regulatory registration, comprising a 
series of sequential discovery and development decisions (6,17).  
A deeper understanding of the drug development process and of its steps helps to explain why so 
many compounds do not reach the approval phase (18).  
3.1.1. Drug Discovery and Laboratory Development 
The first step of the drug development process is entitled drug discovery. Drug discovery is driven 
by unmet medical needs and financial opportunity and focuses on understanding the disease, as 
thoroughly as possible, and on the identification of disease targets and potential therapeutic 
compounds (6).  
Once a target has been identified, researchers conduct studies in cells, tissues and animal models 
to determine whether the target can be influenced by a drug (6,15).  
Afterwards, researchers look for a lead compound, that is to say a promising molecule that could 
influence the target and, potentially, become a medicine. This is done in a variety of ways, 
including creating a molecule from scratch, using high-throughput screening techniques to select 
a few promising possibilities from among thousands of potential candidates, finding compounds 
from nature and using biotechnology to genetically engineer living systems to produce disease-
fighting molecules (15).  
Even at this early stage, researchers already are thinking about the finished product. Issues such 
as the formulation of a medicine and its delivery system (i.e. how the medicine will be 
administered) are critical to a compound becomes a successful new medicine in the future (15).  
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3.1.2. Preclinical Studies 
The drug discovery phase whittles down thousands of compounds to a few hundred promising 
possibilities that are ready for preclinical testing (15). From a total of 5,000 to 10,000 compounds, 
only 250 reach the preclinical phase (19). In the preclinical phase, researchers conduct laboratory 
and animal studies to determine whether a compound is suitable for human testing (15). Before 
the start of any CT, results from preclinical studies or previous human studies should be sufficient 
to indicate that the drug is acceptably safe for the proposed investigation in humans (20). The 
purpose of these preclinical studies is to provide the information necessary to start the CT (6).  
At the end of this phase, which can take several years, around five compounds move to the next 
stage of testing in humans. The pharmaceutical company files a CT Application (in Europe) or an 
Investigational New Drug Application (in United States of America) with the competent 
authorities to begin CT (15).  
3.1.3. Clinical Development 
Before describing the clinical development process it is important to define two concepts inherent 
to this phase: clinical research and CT. 
According to National Institutes of Health, clinical research is defined as “research conducted with 
human subjects (or on material of human origin such as tissues, specimens and cognitive 
phenomena) for which an investigator (or colleague) directly interacts with human subjects. 
Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked 
to a living individual. Clinical research includes: 
 Patient-oriented research: This type of research involves a particular person or group of 
people, or uses materials from humans. This research can include 1) mechanisms of 
human disease, 2) therapeutic interventions, 3) clinical trials, and 4) development of new 
technologies 
 Epidemiological and behavioural studies: These types of studies examine the distribution 
of disease, the factors that affect health, and how people make health-related decisions. 
 Outcomes and health services research: These studies seek to identify the most effective 
and most efficient interventions, treatments, and services” (21).  
According to guideline “E6 – Good Clinical Practice” of the International Conference on  
Harmonisation (ICH), a CT is defined as “any investigation in human subjects intended to discover 
or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational 
product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to 
study absorption, distribution, metabolism, and excretion of an investigational product(s) with the 
object of ascertaining its safety and/or efficacy” (8, p.3).  
To obtain approval from a competent authority to market a new drug for use in humans, a series 
of CT must be conducted. These CT are performed throughout four phases: phase I, II, III and IV. 
Each phase has specific and different requirements for patient types, goals, inclusion/exclusion 
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criteria, design features and expected outcomes. Together, these trials build the dataset for safety 
and efficacy that hopefully will lead to product approval (6).  
The time frame for these CT often is entitled clinical development and requires about 6 to 7 years 
(6). During the clinical development, a new drug is tested in human volunteers. Since this process 
involves both benefits and risks, pharmaceutical companies take great care to protect the safety 
of trial participants and to ensure that they are thoroughly informed about the trial and its 
potential risks so that they can provide informed consent to participate, as required by law. 
Pharmaceutical companies also guarantee that the trials are conducted correctly and with 
integrity and that trial results are disclosed at the appropriate time (15).  
In the past, there were clear boundaries between the four fairly standardized phases of clinical 
drug development. However, the phases have become less well defined as questions previously 
addressed in one phase are being addressed in both earlier and later phases. In part, this new 
approach is designed to accelerate the acquisition of information required for approval and 
successful marketing of a new drug and for collection of full and sufficient safety information as 
early as possible (6).  
Currently, CT can be classified according to when the trial occurs during clinical development 
(phase I, II, III or IV) or by their objectives (human pharmacology, therapeutic exploratory, 
therapeutic confirmatory and therapeutic use). “The phase of development provides an 
inadequate basis for classification of clinical trials because one type of trial may occur in several 
phases” and therefore a classification system based on trial objectives is a more realistic approach 
(20, p.5). Figure 5 illustrates the close but variable correlation between the phases of 
development and types of study by objective that may be carried out during the clinical 
development of a new drug. The shaded circles show the types of study most usually conducted in 
a certain phase of development, the open circles show certain types of study that may be 
conducted in that phase of development but are less usual (20).  
 
 
Figure 5 – Correlation between Clinical Development Phases and Types of Study (20) 
A brief summary of each phase of clinical development is presented below. 
Phase I (Most typical kind of study: Human Pharmacology) 
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Phase I studies are the first studies performed in human subjects (6). This phase starts with the 
initial administration of a new drug into humans (20). Sufficient preclinical information, including 
animal toxicology data, should be available to suggest that the new drug may be effective and 
safe in humans for the proposed indication (6).  
Studies in this phase of development are usually conducted in healthy volunteers. However, there 
are circumstances in which healthy volunteers are not used. Typically, this happens when more 
“toxic” therapies are being tested, such as cancer chemotherapy and antivirals for the treatment 
of the human immunodeficiency virus. In these circumstances, patients with the disease are the 
first individuals to test the new therapy (6).  
The objectives of this type of study are: to assess initial safety and tolerability; to define/describe 
pharmacokinetics and pharmacodynamics; to explore drug metabolism and drug interactions and 
to early estimate drug activity (20).  
Phase II (Most typical kind of study: Therapeutic Exploratory) 
Phase II studies are performed to determine the initial therapeutic efficacy of a drug in patients 
with the condition or disease of interest (6).  
A characteristic of phase II studies is the use of relatively homogeneous populations due to 
narrow inclusion criteria. This feature increases the likelihood of identifying a positive effect and 
decreases confounding variables. On the contrary, the results obtained may not accurately reflect 
the effectiveness of the drug in the more typical heterogeneous population. Phase II studies are 
therefore well controlled and closely monitored (6).  
The primary phase II studies are dose ranging studies and are designed to provide proof of 
principle. A major focus is to find the appropriate dose(s) and regimen for the larger studies 
required in phase III (6,20).  
Several products fail at this phase and are “killed”, which is desirable and necessary before 
moving ahead to the very expensive and labour intensive phase III study program (6).  
Phase III (Most typical kind of study: Therapeutic Confirmatory) 
Phase III studies are design to confirm the preliminary evidence accumulated in Phase II that a 
drug is safe and effective for use in the intended indication and target population (20). These 
studies should provide an adequate basis for marketing approval, allowing extrapolation to the 
general population (6,20).  
The decision to move ahead with phase III studies is a major one because the costs are 
considerably higher than for the two earlier phases together (6).  
Submission of a Common Technical Document or New Drug Application requires at least two well-
designed phase 3 studies that demonstrate both efficacy and safety in a large number of patients 
with the target disease (6).  
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Phase IV (Variety of studies: Therapeutic Use) 
Research on a new drug does not end when the discovery and development phases are 
completed and the product is on the market. Instead, pharmaceutical companies carry out 
extensive post-approval research to monitor safety and long-term side effects in patients using 
the medicine. The competent authorities require that pharmaceutical companies monitor a 
medicine for as long as it stays on the market and submit periodic reports on safety issues. 
Pharmaceutical companies must report any adverse events that happen from use of the medicine 
(15).  
Phase IV studies are performed after a new drug obtains marketing approval. This type of studies 
serves multiple purposes and comprises many different kinds. In general, characteristics of phase 
4 studies are that they can be very large and have a more simple study design. Even though these 
studies were not considered essential for initial approval, they provide additional data that could 
change the prescribing information or the use of the drug (6).  
This research phase is essential to improving researchers’ and clinicians’ understanding of 
medicine’s potential uses and its full benefits for health and quality of life (15).  
3.1.4. Regulatory Registration 
If the results of all three CT phases indicate that the new medicine is safe and effective, the 
sponsoring company submits a Common Technical Document (in Europe) and/or a New Drug 
Application (in United States of America) to the competent authorities. These applications are a 
request for competent authorities approval to market the new medicine and contain the results 
and data analysis from the entire CT program as well as the earlier preclinical testing. It also 
comprises proposals for manufacturing and labelling the new medicine (15,18).  
Scientists at competent authorities carefully review all the data from all of the studies on the 
medicine and, after weighing the benefits and risks of the potential medicine decide whether to 
grant approval (15).  
3.2. Current R&D Model and New Trends 
Designed in the early 1960s, the model for pharmaceutical innovation, which is represented in the 
Figure 6, has remained practically unchanged for nearly 50 years. During a period when most 
other research-based industries have made frequent modifications to their R&D process, the 
pharmaceutical industry continues to utilize a drug development process that is complex, 
inefficient, risky, expensive and time consuming (22).  
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Figure 6 – Current Drug Development Process (23)  
On average, it takes about 10 to 15 years for a new drug to complete the journey from initial 
discovery to the market (15). The time for exclusivity of product manufacturing and sales by the 
drug’s originator company is often short after product approval. The majority of drug patents 
have only about 5 years left after product approval, although a patent exists for 20 years. This 
situation relates to patenting of a drug during the early research stage and the long time frame 
for R&D, which uses up the patent life before approval (6).  
High attrition rates are another major challenge for pharmaceutical industry (22). Of every 5,000 
to 10,000 compounds synthesized, on average, only 5 are tested in CT and only one of these is 
approved (6). The medicines that reach CT have a chance of less than 12% of being approved (18).  
Additionally, there are other constraints, namely the reimbursement environment is increasingly 
restrictive; a large number of top-selling products are losing their patents and the regulatory 
environment has become extremely restrictive and much more risk averse (24).  
Long development times coupled with very low success rates translate into high overall R&D costs 
for the pharmaceutical industry (22). The average R&D investment for each new medicine is $2.6 
billion, including the cost of failures (18). Clinical spending rises as we proceed from phase I to III, 
directly related to the size of the CT and their greater diagnostic and monitoring complexity (6).  
The biopharmaceutical industry is continually adapting to produce innovative treatments more 
efficiently (15). Biopharmaceutical companies are re-examining old and inefficient models of R&D 
and embracing new approaches to improve productivity and performance. In particular, 
biopharmaceutical companies are increasing their utilization of global outsourcing, expanding 
their use of information technologies in CT protocols and patient recruitment, and speeding the 
adoption of improved clinical study designs, including adaptive CT. Most importantly, many 
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biopharmaceutical companies are reassessing their focus on R&D strategies that emphasized 
broad diseases areas with large potential for sales, or blockbuster drug development strategies, 
and instead are favouring those that address smaller patient populations, specialized care, and 
unmet medical needs (25). To address the most complex scientific and technological challenges, 
partnerships and collaborations are becoming increasingly common among researchers from 
biopharmaceutical companies, academic medical research centres, non-profit organizations, 
patient advocacy groups, and others. In working together to address these challenges, partners 
share risks and are able to exchange intellectual, financial, and in-kind resources (18).  
Precompetitive partnerships, which seek to advance basic research, are a growing part of this 
approach (15). An example of these partnerships is the European Union’s (EU) Innovative 
Medicines Initiative (IMI), a public-private partnership launched in 2008 between the European 
pharmaceutical industry, represented by the Federation of Pharmaceutical Industries and 
Associations, and the EU, represented by the European Commission. The IMI aims to improve 
health by speeding up the development of, and patient access to, innovative medicines, 
particularly in areas of unmet or social need. It does this by facilitating collaboration between the 
key players involved in healthcare research: academic institutions, pharmaceutical companies and 
other industries, small and medium-sized enterprises, patient organisations and regulatory 
authorities (26).  
The majority of the biopharmaceutical companies now acknowledge that small incremental 
enhancements in R&D efficiency may not be sufficient. It is necessary a transformational overhaul 
of the R&D paradigm (25).  
3.3. Clinical Research in Portugal 
The pharmaceutical industry is increasingly selective regarding the locations to conduct their CT, 
giving priority to countries offering better conditions. Portugal is not among these countries and 
has been losing its competitiveness progressively (19).  
The differences in the transposition of the EU CT Directive by the various Member States were 
already recognized as one of the main factors of loss of efficiency in the EU and inequality 
between Member States (19).  
According to information available on the database clinicaltrials.gov only 1,216 of the 54,440 
clinical studies conducted in Europe, between 2000 and April 2015, were carried out in Portugal. 
The Belgium, a country with a number of inhabitants similar to Portugal, conducted 6,020 of the 
54,440 clinical studies in the same time frame. These data evidence that Portugal is still far away 
from the European reality (27).  
The number of CT submitted in Portugal between 2006 and 2014 decreased 21%, from 160 to 127 
studies. 2011 was the year with lowest number of CT submitted since 2006 until 2014, with only 
88 trials. 
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Figure 7 – Number of CTA Submitted, Authorised and Not Authorised in Portugal by Year (2006-
2014) adapted from INFARMED Website (28) 
(CTA – Clinical Trial Application) 
Portugal has also a very low recruitment rate compared with other countries with a similar 
number of inhabitants, such as Belgium and Czech Republic. The low number of patients enrolled 
in Portugal is the result of several factors, namely the reduced number of sites that participate in 
each trial conducted at our country in comparison with other countries that have more sites 
conducting the same trial. Moreover, the ability of the Portuguese sites to recruit patients is 
clearly lower than the ability of other countries, and often falls short of the planned (19).   
The majority of the CT submitted in 2014 were phase III (81%).  On the contrary, only 10% of the 
CT submitted in 2014 were phase I. The number of phase II CT submitted between 2006 and 2014 
has not varied much (20% in 2006 and 24% in 2014). However, there were a reduction in the 
number of phase III and IV CT submitted (phase III: 104% in 2006 and 81% in 2014; phase IV: 27% 
in 2006 and 12% in 2014) and an increase in the number of phase I CT submitted between 2006 
and 2014 (2% in 2006 and 10% in 2014) (28). 
The therapeutic areas with more CT authorized in Portugal, by year, are oncology, nervous system 
and infectious diseases. Together, these therapeutic areas represent more than half the number 
of trial authorized (28).  
Despite these scenario, in 2012 the pharmaceutical industry invested 36 million euros in clinical 
research in Portugal, which contributed to a saving in the public expense of 3,5 million euros. The 
CT activity was responsible for a Gross Value Added of 72 million euros in 2012 and for each euro 
that is invested in clinical research, it is estimated that there is a return of 1.98 euros for the 
Portuguese economy. The clinical research is one of the activities with the highest return of 
investment of the country (19).  
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The national regulatory framework for the conduction of CT is currently governed by the Law 
21/2014 of April 16th, which transposes the EU Directive 2001/20/CE, April 4th. The Law 21/2014 
of April 16th aims to contribute to the promotion of clinical research in Portugal and to increase 
the competitiveness and transparency in this sector (29).  
The entry into force of this law has overcome some of the major constraints of the clinical 
research area in our country as shown in Table 1. (19) 
Table 1 – Comparison Between the Clinical Research Framework in Portugal Before and After 
the Law 21/2014 of April 16th (4,19) 
Before After 
Uncompetitive deadlines for approval of CT 
Average time for approval of a CT in Portugal =  
more than 70 days 
Opinion of the ethics committee within not 
more than 30 days 
 
Authorization of the INFARMED and CNPD 
within not more than 30 days 
 
Mandatory approval of CT by the Comissão 
Nacional de Proteção de Dados (CNPD; 
National Committee of Data Protection) 
without legally defined deadlines 
Absence of legal deadlines for approval of the 
CT financial contract 
Approval of the financial contract within not 
more than 15 days 
Lack of a platform to promote and support the 
clinical research 
Creation of the Registo Nacional de Estudos 
Clínicos (National Register of Clinical Studies) 
 
3.4. Regulatory Framework 
Any health professional working in the clinical research area needs to deal with and respect the 
applicable ethical, legal and regulatory requirements (5). A brief description of the main 
guidelines and laws in the clinical research area is presented below.  
The ICH-GCP E6 guideline “is an international ethical and scientific quality standard for designing, 
conducting, recording and reporting trials that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety and well-being of 
trial subjects are protected, consistent with the principles that have their origin in the Declaration 
of Helsinki, and that the clinical trial data are credible.” (8, p.1) This guideline sets forth a 
tripartite standard for the conduct of CT among the United States, EU, and Japan (17).  
The Declaration of Helsinki is a statement of ethical principles for medical research involving 
human subjects and was first developed in 1964 by the World Medical Association. This 
Declaration has undergone several subsequent revisions over the years; the last one was in 2013 
(5,30).  
The Directive 2001/20/CE, April 4th (31), also known as the EU CT Directive, establishes the 
requirements for the conduct of CT of experimental drugs in the EU. This directive was first 
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transposed into the Portuguese law by the Law 46/2004 of August 19th (32). The Law 46/2004 was 
repealed by the Law 21/2014 of April 16th (4), in force since June 2014. 
The Directive 2005/28/CE, April 8th (33), also known as the EU GCP Directive, lays down the 
principles and detailed guidelines for GCP in CT of experimental drugs in Europe (34). This 
directive was transposed into the Portuguese law by the Decree-Law 102/2007 of April 2nd (35). 
The Directive 95/46/CE, October 24th (36), concerns the protection of subjects personal data and 
the free movement of such data. This directive was transposed into the Portuguese law by the 
Law 67/98 of October 26th (37). 
3.5. The Role of Pharmacovigilance 
Pharmacovigilance refers to the science and activities related with the detection, assessment, 
understanding and prevention of ADR and other problems linked to drugs (10). It has a crucial role 
in protecting Public Health through the ongoing evaluation of the risks and benefits of drugs, 
being a key tool in the monitoring and guarantee of drug safety (11).  
Indeed, the drugs are neither harmless nor absolutely safe and therefore its use may cause, in 
certain circumstances and in some of its users, ADR (12).  
The ADR represent an important Public Health problem since they result in high rates of mortality 
and morbidity, entailing consequently great costs for health systems. A study developed in 1998 
in the United States by Lazarou, et al. estimated that ADRs are between the 4th-6th cause of 
death (10).  
The CT performed to support the granting of a marketing authorization to a medicine have several 
limitations as regards the identification of possible ADR, namely: reduced number of subjects 
exposed to the experimental medication; restricted inclusion criteria that exclude subjects with 
associated pathologies and that take concomitant medications and the tendency to not include 
population groups such as the elderly, children and pregnant women. Additionally, certain events 
of lower incidence or which occur over the long term are difficult to detect during the CT since 
they are limited in time. Thus, the safety profile of a medicine is largely unknown when the 
marketing authorization is granted (10,11).  
“No drug which is phamacologically effective is entirely without hazard. The hazard may be 
insignificant or may be acceptable in relation to the drug’s therapeutic action. Furthermore, not 
all hazards can be known before a drug is market; neither tests in animals nor clinical trials in 
patients will always reveal all the possible side effects of a drug. These may only be known when 
the drug has been administered to large number of patients over considerable periods of time 
(11, p.22).” (Committee on Safety of Drugs, U.K.; 1969/1970)  
The phase after the granting of the marketing authorization of a medicine is of great importance 
for the detection of ADR, since the medicine is used in a real context and in a widened and 
heterogeneous population. Indeed, the majority of the ADR occur in this phase (10). The 
awareness that the pre-marketing CT do not allow an adequate knowledge of drug safety due to 
23 
methodological reasons resulted in the creation of structures to monitor the drug safety during 
their marketing (38).  
The creation of Pharmacovigilance Systems worldwide began to appear in the 1960s, after the 
knowledge by the community of the Thalidomide Tragedy. This disaster was caused by the 
administration to pregnant women of thalidomide, a drug promoted for use by this specific 
population, which resulted in thousands of cases of phocomelia in children exposed to this unsafe 
drug during the gestation period.  Due to the inexistence of systems to monitor drug safety after 
their marketing authorization, it was necessary four years (from 1957 to 1961) to identify the 
teratogenic effects of thalidomide, despite the emergence of many thousands cases of 
phocomelia at that time (10,39).  
The Thalidomide Tragedy was first discussed in 1961, highlighting the need to constant drug 
surveillance after their marketing. Thus, during the Sixteenth World Health Assembly, in 1963, it 
was decided to implement the global monitoring of ADR, aiming the detection, recording and 
evaluation of ADRs, in order to minimize the risk associated with the use of drugs (10).   
Thereby, it was developed in 1968 a pilot project of international research and monitoring, 
coordinated by the World Health Organization (WHO), which aimed to create an International 
Pharmacovigilance System. This system aimed to develop the ADR detection system, called WHO 
Programme for International Drug Monitoring, and was initially composed of the following 
countries: United Kingdom, United States of America, Federal Republic of Germany, Canada, 
Netherlands, Ireland, Sweden, New Zealand, Australia and Czechoslovakia, which created the 
respective National Centres of Pharmacovigilance (10,39).  
The program is coordinated since 1978 by the Uppsala Monitoring Centre (UMC) in Uppsala, 
Sweden. In this centre are collected, processed and stored the spontaneous reports of all member 
states and is also from here that are issued warnings, related with potential safety problems, to 
the regulatory authorities of each member country (10).  
Each country has currently its own monitoring systems of marketed drugs. To sum up, the pilot 
project, created in the 60s, led to the development of different national pharmacovigilance 
systems that still exist all over the world (10). The Portuguese Pharmacovigilance System is an 
example of those systems. 
The drug surveillance carried out by the Portuguese Pharmacovigilance System is based mainly on 
spontaneous reporting of ADR made by health professionals or any ordinary citizen to the 
National Competent Authority (NCA) (10).  
 “A spontaneous report is an unsolicited communication by a healthcare professional, or 
consumer to a competent authority, marketing authorisation holder or other organisation (e.g. 
Regional Pharmacovigilance Centre, Poison Control Centre) that describes one or more suspected 
adverse reactions in a patient who was given one or more medicinal products and that does not 
derive from a study or any organised data collection systems where adverse events reporting is 
actively sought.” (40, p.8) 
24 
The reports are submitted in writing, using the paper reporting forms, and are sent by post or fax 
or can be communicated by telephone or e-mail to the NCA. The report can also be done through 
the filling of the online reporting form on the ADR Portal (Portal RAM) (10,38).  
Should be reported to the NCA all suspected serious ADR, even if they are already described in the 
summary of product characteristics (SmPC); all suspected ADR not described in the SmPC, 
regardless of the seriousness, and all suspected of increase in the frequency of ADR (serious and 
non-serious) (12).   
The spontaneous reporting systems have many advantages, namely: cover all the medicines 
available on the market and its entire life cycle; are cost-effective methods; encompass the entire 
consumer population of medicines; do not interfere with the prescription habits and allow the 
identification of rare ADR (38). Notwithstanding all these advantages, the main value of the 
spontaneous reporting systems lies in early detection of possible drug safety problems that have 
gone unnoticed until then (11,41).  
However, these systems have as a major limitation the underreporting of suspected ADR. In other 
words, the underreporting means that the cases spontaneously reported to the NCA only 
represent a small portion of the number that has truly occurred (10,41,42).  The underreporting 
of suspected ADR limits the risk assessment of medicines and delays the generation of risk signals 
(10). It is also important to highlight that underreporting does not only affect older drugs and 
non-serious ADR. New drugs and serious ADR also suffer from underreporting (41).  
For a spontaneous reporting system to be effective, it is essential the active participation of their 
reporters and therefore the underreporting of ADR remains as a key problem in all countries (39).  
Spontaneous reporting systems should be seen as generators of hypotheses that often need to be 
further investigated by other methods, such as pharmacoepidemiological studies, especially in 
order to confirm and quantify the risk (11).  
In an attempt to facilitate spontaneous reporting in Portugal, the INFARMED (the Portuguese 
NCA) developed the ADR Portal. This is a tool for online ADR reporting where health professionals 
and patients can report ADR by filling out an online reporting form (43).  
Additionally to the ADR report submission, the ADR Portal also contains pharmacovigilance 
information, news and useful links. In the ADR Portal the citizens can also found a Frequently 
Asked Questions (FAQ) section and objectives, definitions and contact details within the scope of 
pharmacovigilance (43).  
The ADR Portal comprises internal management features which allow the communication and 
information management between the Regional Pharmacovigilance Units and the INFARMED, the 
system’s coordinator. Reports submitted into the ADR Portal become automatically available for 
the corresponding Regional Pharmacovigilance Unit and are subsequently validated and 
processed on the Portal’s platform by their staff. Then, they are uploaded into the Portuguese 
Pharmacovigilance System Database (SVIG) and after the handling by the pharmacovigilance team 
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of the INFARMED are made available for electronic transmission to the EudraVigilance and 
VigiBase databases (43).  
In 2004, it was created by the INFARMED the national database named SVIG for the registration of 
ADR reported to the SNF. In this database are introduced the reports of suspected ADR that 
occurred in Portugal and sent by: 
 the various Regional Pharmacovigilance Units of the mainland Portugal; 
 health professionals or citizens of the autonomous regions (Madeira and Azores), that 
report directly to INFARMED; 
 the pharmaceutical industry – Marketing Authorisation Holders (MAH) (12).  
The SNF is connected with the VigiBase, the WHO global database created in 1968 that receives 
the reports of ADR from member countries. The VigiBase is updated on a continuous basis with 
new Individual Case Safety Reports (ICSR) and it is developed and maintained by the UMC on 
behalf of the WHO. By May 2015 this database contained over 11 million ICSR (12,44).  
The SNF is also connected with the European Medicines Agency (EMA) database, the 
Eudravigilance Data Base Management System, created in December 2001. It is a centralized 
European database of suspected ADR that occurred with the utilization of medicines that are 
marketed or being studied in CT in the European Economic Area (12,45).  
In July 2012 the new European pharmacovigilance legislation, which comprises the Directive 
2010/84/EU and the Regulation (EU) No 1235/2010, come into effect. This legislation amended 
the existing pharmacovigilance laws contained in Directive 2001/83/EC and Regulation (EC) No. 
726/2004 (46).  
The implementation of the new pharmacovigilance legislation has brought new responsibilities for 
regulators and the pharmaceutical industry in the EU (47).  
Since July 2012, all individual European citizens can report their suspicions of ADR directly to the 
NCA, without having to report them first to a health professional (10,47).  
It is also required the creation of national web portals of medicines connected with the European 
portal, in order to allow disclose relevant information to the community in general. This relevant 
information includes SmPC, package leaflets, reports assessment, summaries of risk management 
plans as well as the different ways of reporting suspected ADR to the NCA by the citizens (health 
professionals, patients, etc.), including the online notification (12).  
The definition of ADR has also changed and become more comprehensive, including now not only 
the noxious and unintended effects resulting from the use of medicinal products within the terms 
of the marketing authorization but also outside including overdose, off-label use, misuse, abuse 
and medication errors and occupational exposure (12,40).  
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4. On the Job Training 
This section provides a full description of all the activities that I carried out during the ten months 
of curricular training in each of the sub-units of the UFC: the CIC, the SBM and the URFLVT. Firstly, 
I am going to describe the activities that I developed in the CIC, then the activities developed in 
the SBM and lastly the activities developed in the URFLVT. 
4.1. Centro de Investigação Clínica  
My internship at CIC was divided in two parts, as previously mentioned.  The first part started on 
September 2nd and lasted until 10th November. The second part started on 13th March and lasted 
until 3rd July. 
In my first two weeks at CIC I met the team that collaborates in the conduction of the clinical 
studies, I got to know the physical space of the centre and understood how it was organized, I 
read the protocols of each clinical study that was being conducted at the centre, I became familiar 
with the documents and laboratory material of each clinical study and I learned how to process 
laboratory samples. I also received the necessary training, given by the two senior SC who work at 
the CIC, to perform all the activities of a SC. 
A SC can take over a great number of responsibilities and activities. Throughout this sub-section I 
am going to describe all the activities that I carried out as SC and some other activities that I did 
not carry out but that I consider to be important to understand how a CT is implemented, 
conducted and completed.  
Study Visits 
The trial site visits conducted by the sponsor/Contract Research Organization (CRO) can be 
divided into four categories: Site Qualification Visit (SQV), Site Initiation Visit (SIV), Interim 
Monitoring Visits and Site Closure Visit (SCV) (48). The feasibility phase can be considered a pre-
CT phase in which the interest of the investigators to conduct the trial and the conditions of the 
site are assessed by the sponsor/CRO.  
The subjects trial visits at the centre can be divided in the following visits: screening visit, baseline 
visit, regular visits, unscheduled visits (if necessary), final visit and post-study follow-up visit(s).  
Feasibility Phase (Investigator/Site Selection) 
The selection of the investigators and sites for the conduction of a trial is a critical issue. Shortly, 
to do this selection is necessary to evaluate three criteria: qualification, recruitment potential and 
relationship needs (5).   
The investigators and the sites must be qualified. They must have the proper experience in the 
therapeutic indication studied in the trial, trained staff, proper facilities and other pertinent 
qualifications specific for each trial. The site must also have access to the patients, either from 
their own practice or from referrals. The last criterion is relationship needs, since typically there 
are sites that are of importance because of relationships or strategic importance (5).  
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In the feasibility phase the sponsor/CRO contacts the PI of their interest to assess the interest and 
capacities of these PI/sites to conduct the trial. Generally this contact is done along with the 
sending of a feasibility questionnaire to the PI of interest in order to evaluate and select the most 
suitable PI/sites. This questionnaire basically consists of several questions about the conditions of 
the site (facilities, material, human resources, and clinical research experience), the experience of 
the PI and the number of patients that the PI expects to recruit. The feasibility questionnaire is 
completed by the PI with the support of the SC and then is sent back to the sponsor/CRO. After 
this process, the PI waits for feedback.  
Site Qualification Visit  
The next step after the feasibility phase is the conduction of a qualification visit.  
The SQV consists of a visit of the sponsor/CRO to the site in order to asses if the PI/site truly 
meets all the requirements for the conduction of the trial. This visit is done by the study monitor 
of the trial, which meets with the PI and SC. In the SQV the PI signs the confidentiality agreement 
and the study protocol is presented and discussed. In this visit, other issues are discussed, namely: 
the number of patients that should be recruit and the financial contract. 
The SQV can be very different according to the experience that the sponsor/CRO has with the site. 
If it is the first time that the sponsor/CRO visits the site, usually the SQV lasts longer. If the 
sponsor/CRO already had a past experience with the site, the SQV can be quicker or can be even 
by telephone.  
After this phase, the site is contacted by the sponsor/CRO to be informed whether it was selected 
or not. 
Investigator Meeting 
When all of the investigators and the sites are selected to participate in a CT, the sponsor or CRO 
responsible for the trial will hold an Investigator Meeting (49).  
Representatives from each site, generally the PI and SC, will participate in the meeting together 
with representatives from the sponsor’s clinical team, regulatory affairs, data management and 
quality assurance departments. (49).  
The Investigator Meetings can be considered as a training session for the participants.  At the final 
of this type of meeting, the participants should understand completely the protocol and how to 
conduct the CT. This is also an excellent opportunity for the investigators and their staffs to ask 
questions about the trial and trial conduct (49).  
 
During my training I did not participate or provided support to any feasibility process, SQV or 
Investigator Meeting, but everything about these processes was explained to me by the seniors 
SC. I did not attend to any SQV because no SQV took place during my internship at CIC and 
regarding the Investigator Meetings, only the senior SC at the CIC were authorised to attend.  
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Site Initiation Visit  
Before the start of trial enrollment at the site, a SIV is conducted (48). This visit is characterised by 
the implementation of the CT in the site and after the SIV, the site is considered officially started 
and subject recruitment can begin (49).  
The study monitor will schedule the SIV with the PI and SC by phone or e-mail and will send a 
follow-up letter in writing in order to confirm the date and time of the visit and the staff’s 
availability for the visit. All study staff participating in the trial should be present in this important 
visit (49).   
For site initiation, the site must submit the required regulatory documents, have the protocol and 
the Informed Consent Form (ICF) approved by the Institutional Review Board, have a contract 
with the sponsor, and have all other issues in order if applicable, namely the validation of sample 
shipping and training on Electronic Data Capture (5).  
During this visit, the monitor will review in detail the protocol (design of the trial, inclusion and 
exclusion criteria, experimental drug, etc.); the ICF; the experimental drug dispensation and 
accountability; the adverse experience and serious adverse experience reporting; the CRF 
completion; the PI and staff responsibilities (delegation log); the regulatory documents and 
source documentation and will answer any question that the site may have (5,49).  
The SIV is also a training meeting. It is the last training on the protocol that the investigators and 
their staff will have before beginning to recruit and enroll subjects in the trial (49).  
I had the opportunity to attend to a SIV during my internship at CIC. 
Screening Visit 
Before carrying out the screening visit, the potential trial participants are approached in order to 
assess their interest in participate in the clinical study. They can be approached in a routine visit 
to the hospital by the study investigator; contacted by phone or referenced by physicians of other 
hospitals or health centres. 
After this first contact, a visit is scheduled to give more information about the study, discuss this 
information with the patient and clarify any doubts the patient may have. If the patient accepts to 
participate in the clinical study, an ICF is signed and dated by the patient and the investigator and 
then a screening visit is conducted. The ICF must always be signed before carrying out any 
procedure of the trial and a copy of this document must be given to the patient.  
The screening visit allows to determine which of the potential trial participants can actually be 
included in the study. 
During this visit the SC helps the investigator with any doubt about the ICF, protocol and 
amendments to these documents. The SC also informs the patients about the logistics of the 
procedures to be conducted in the screening period (e.g., an ophthalmological exam) and 
highlights their availability in helping them with any situation related to the CT (e.g., if the patient 
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does not feel well he/she can contact the SC). The SC also gives support, if necessary, to the rest 
of the team such as psychologists, nurses, laboratory technicians, among others. 
The screening period is the time available to conduct the screening exams/tests and for the 
laboratory determine the eligibility criteria. This period of time exists because of the logistics of 
performing the procedures necessary to include the trial participants (e.g., if a trial needs a 
genetic confirmation of the disease of interest as part of the inclusion criteria, then the time spent 
waiting for the central laboratory results is part of the screening period) (5).  
The SC has the role of scheduling the exams/tests required for the trial and provides this 
information to the patients. Whenever necessary, the SC also organizes the transport of the 
patients.  
If a patient meets all the inclusion criteria it is included in the study and a baseline/randomization 
visit is scheduled. 
I provided support in several screening visits of different studies. 
Screen Failure 
In all CT some potential trial participants will fail to pass the screening criteria. When this situation 
happens, the study subject is considered a “screen failure” since he/she does not meet one or 
more criteria required for participation in the clinical study and therefore cannot be included in it 
(50,51).  
It is important to document the reasons for screen failures in any CT. This record provides 
information in relation to the feasibility of recruiting study subjects from each site and may 
justified and result in protocol modifications based on frequency of screen failures when the 
motive for screen failures is common among the study population of interest. Additionally, some 
trial protocols allow rescreening of potential trial participants after a certain time interval (50).   
To be eligible to participate in a CT, a patient must meet all of the inclusion criteria and none of 
the exclusion criteria (52).   
Determining appropriately the study eligibility is as important as the informed consent process. 
The sponsor/CRO, ethics committee and competent authorities always review these two 
processes because they direct affect the health and safety of the study subjects (52).  
During my training I conducted some screening visits that resulted in screen failures. It is always 
complicated to the team when this happens since a participant is lost, the effort of the team to 
include the patient is wasted and a patient lost an opportunity to try an innovative medication for 
his/her disease. Besides this, it is never easy to communicate to the patient or their relatives that 
he/she cannot be included in the trial despite his/her will. 
Baseline Visit 
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The baseline visit is carried out at or very close to the time when the subjects are randomized to 
trial treatment/intervention (53).  
This is a critical visit as all observations recorded at this visit will be the basis for comparison with 
all observations made while on the study treatment. Therefore, a complete medical history and 
physical examination usually are performed, together with laboratory tests. All concomitant 
medications are also recorded. Any special tests, assessments, or procedures relating to study 
endpoints are carried out at this visit or are scheduled, if not yet already done (53).  
In CT that evaluated experimental medications, the baseline visit is concluded by dispensing by 
the first time the study medication, scheduling the next visit and arranging for any procedures 
needed for the next visit (53).  
In this visit the SC has the role of explaining to the patient how to take the experimental 
medication, the importance of the compliance and accountability of study medication (the 
patients should always return the blisters/boxes/bottles of study medication) and how to fill the 
medication diaries, if they exist in the study. 
I also provided support in several baseline visits of different studies. 
Regular Visits 
Following the baseline visit, the subject is seen by the investigator at intervals specified in the 
protocol which occur at determined time points from the date of the baseline visit (53).  
These visits are intended primarily to monitor the progress of the subject and its tolerability 
regarding the study intervention. In each regular visit, a brief medical history and physical 
examination are undertaken and any adverse events or findings are sought. Subject compliance 
regarding medication is also generally evaluated since the subject was asked to bring the unused 
study medication to do its accountability. The regular visits are concluded by dispensing the study 
medication, scheduling the next visits and arranging for any procedures/tests necessary for the 
next visit (53).   
In practice what I did as a SC in these visits is described below. 
When a subject had a trial visit it was generally necessary contact him/her, a few days before or 
on the day before, in order to remember of the occurrence of the visit or to remember of other 
issues, such as remind the patient that needs to come in the fasted state to the visit. 
Generally on the day preceding the study visit I prepared everything that was necessary to 
perform it.  Therefore, to prepare a visit I first looked at the flowchart of the trial to check which 
procedures had to be performed. Then I pulled off the patient's folder of study cabinet and 
gathered together the following sheets: blank sheets to the investigator fill out with the 
description of the visit; a standard sheet, created by the SC, to record the vital signs; Interactive 
Voice Response System (IVRS) codes and IVRS sheets, if applicable; a sheet for the request of 
experimental medication to pharmaceutical services – the prescription sheet; a requisition, duly 
completed, if the collection of laboratory samples was necessary, and other sheets specific of 
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each trial and necessary to the visit, such as sheets to schedule ophthalmologic or magnetic 
resonance imaging exams. If there were laboratory samples, I also pulled off the respective 
laboratory kit and prepared the collection tubes (filled the labels of each tube with the required 
information and pasted the labels in the respective tubes) necessary to the visit of the next day. 
Unscheduled Visits 
Sometimes the patients develop complications and may need to be seen between scheduled 
visits. The reasons for, and findings obtained during unscheduled visits must be recorded as study 
data (53).  
I provided support in some unscheduled visits, namely in the CT of Multiple Sclerosis conducted at 
the centre. In this disease the occurrence of relapses is common and therefore when a patient is 
participating in a CT and has a relapse, an unscheduled visit should be performed.  
Final Visit/End of Treatment Visit 
The final visit is the last visit of the trial wherein the subject is still receiving the study 
intervention. This visit includes essentially the same observations/procedures that the baseline 
visit in order to compare the outcomes of this visit with those of the baseline visit. Additionally, 
the same type of information collected at regular visits is obtained to cover the interval since the 
last regular visit (53).  
At the end of the final visit, study intervention is ended and one or more study follow-up visits are 
scheduled (53).  
Exceptionally, it is also necessary to perform a final visit when a subject ends the trial 
prematurely, e.g., because of intolerable side effects or other reasons. In this case, all attempts 
must be made to schedule the final visit with the subject in order to perform all the necessary 
observations/procedures. The completion of the final visit, even prematurely, is a way to 
guarantee that the data obtained from the subject until that moment may still be analysed and 
included in the results of the study (53).  
I only provided support to one final visit. 
Post-study Follow-up Visits 
Subjects should be seen at least once after finishing their study participation to guarantee that 
they are not suffering any sequel that might be associated with their study involvement (53).  
The post-study follow-up visits are generally scheduled at 1 week to 1 month after the final visit, 
depending on the possible duration of effects of the study intervention (53).  
I provided support to three post-study follow-up visits. 
Site Closure Visit  
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When the trial is completed or it is terminated early at the site, a SCV should be performed in 
order to the study be properly “closed”. This cannot happen until all of the subjects have 
completed the course of the trial, were dropped or withdrawn. At the SCV, all the documents are 
verified to make sure they are in order, final Source Data Verification (SDV) is carried out, all the 
queries and follow-up on serious adverse events are closed out and the drug is reconciled and 
generally retrieved from the site for destruction (5,49).  
Schedule of Subjects Trial Visits and Observations 
The protocol must provide a schedule of subject visits, generally represented as a flowchart, with 
details about when these will be conducted and what information will be gathered at each visit. 
This section of the protocol is strictly followed by the study staff including the SC and is an 
excellent working tool (53).  
It is important to specify the timing of the trial visits with a window of plus or minus a short 
number of days, if possible, to enable some flexibility in scheduling appointments (53).  
The SC is responsible for ensuring that all subject visits are scheduled and performed at the right 
time within the window of each visit. If a visit is conducted out of its window, a finding is noted 
for the centre, which is not good for the statistics of the centre and its reputation.  
Request of Study Medication 
The request of study medication can be done via IVRS or Interactive Web Response System 
(IWRS).  
The use of an IVRS or IWRS for management of CT has become very popular, especially for 
multinational CT. The IVRS or IWRS has the capability of functioning without human intervention, 
which makes worldwide access possible. For this reason, these systems are an ideal tool for 
central randomization and drug management in clinical research (17).  
The IVRS is a voice support system that uses the telephone as the interface between the end-user 
and a central computer. To use the system the SC needs to dial a specific number (different for 
each study) which addresses the IVRS. Then a set of instructions and options is given by a pre-
recorded voice (in any language) and the SC can select the desired option by pressing the keys of 
their telephone in order to receive the desired information (54,55).  
The IWRS is the web-based equivalent of IVRS, where instead of the telephone, a secure webpage 
is used as the interface with the central computer, allowing the end-user to select menu options 
and to enter and receive data and instructions (54).  
These systems allow several actions namely: patient screening and screen failure tracking, remote 
patient randomization and study medication assignment to subjects (55,56).  
After the assignment of the study medication through one of these two systems it is necessary to 
fill in the prescription sheet with the information provided by the IVRS or IWRS system. This sheet 
has generally, regardless of the study, similar information. The first part of the sheet has the name 
34 
of the study; the screening or randomization number of the patient; the number of the visit or 
dose of study medication and the number of the kit(s) assigned. This information can be filled in 
by the SC. The second part consists of information about the study medication namely the batch 
number, the batch expiration date, the total volume of study medication prepared (in the case of 
infusions) and other information. This part is filled in by the pharmacist.  
The prescription sheet must always be signed and dated by the investigator before being sent to 
the pharmaceutical services. In the CIC, the sheet is sent to the pharmaceutical services by e-mail. 
Afterward, the pharmaceutical services fill in the sheet and send by a designated person the 
requested medication along with a copy of the sheet. The original sheet is then sent to the 
pharmaceutical services. 
Before I start using the IVRS and IWRS I received training from the senior SC who taught me how 
to register a new screening of a subject, to randomize trial participants, to assign the study 
medication, to register a screen failure in the system, among others.  
Accounting of Study Medication Returned 
Generally the accounting of the study medication returned by the subjects is not done by the SC 
but only by the pharmacist at the pharmaceutical services. However, in one study conducted at 
the centre, the SC also do the accounting of study medication since this information is necessary 
to fill in the CRF of the study.  
Measurement of Vital Signs 
At each study visit, and if necessary according to the flow chart of the study, I measured the vital 
signs of the patient, namely the blood pressure, heart rate, tympanic temperature, respiratory 
rate, weight and height. 
Performing ECG 
Some trials visits require the realization of one or more ECG. In the CIC, the SC are responsible for 
performing ECG in trial participants. I was instructed by the senior SC on how to deal with the 
electrocardiograph and how to perform an ECG. 
In some CT, it is required to send the ECG performed to the central team of the study. In this case, 
the ECG is transmitted from the electrocardiograph to the central team through telephone 
network. This task is also a role of the SC. 
I provided support in the realization of several ECG but only did one without help since only at the 
end of the training I felt confident to perform this procedure. On the other hand, I sent several 
ECG to the central team. 
Processing Laboratory Samples 
This activity can be divided into a number of sub-activities. First, I helped the laboratory 
technician, which withdraws the blood samples, by giving her the required tubes for the blood 
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collection. After the collection, I gently inverted the tubes according to the instructions presented 
on the laboratory manual specific for each study. Then, I transferred the tubes to the area where 
they would be processed, and waited to allow the clotting of the blood or centrifuged 
immediately, depending on the instructions of the laboratory manual. When the centrifugation 
was finished, and if necessary, I transferred the plasma/serum to the transference tubes and 
proceeded to the packaging of tubes for their transport. In some studies it was also necessary the 
preparation of smears. 
Additionally to the blood samples, in some visits it is also necessary to collect a urine sample and 
send it along with the blood samples. In some visits of specific CT a urine dipstick test is also 
performed by the SC and the results recorded. 
The samples can be sent to the external laboratories at room temperature, refrigerated or on dry 
ice. If the samples need to be shipped on dry ice it is necessary to request the sending of dry ice in 
advance, preferentially by fax. 
Entry of Data into the CRF and Query Resolution 
A CRF is a document on which the information, required by the trial protocol, about each trial 
subject is recorded.  It can be a printed, optical or electronic document and its design vary from 
trial to trial. The data recorded on the CRF will be used to perform the statistical analysis of the 
trial (8,57).  
In the end of each visit, the information collected according to the trial protocol during the same 
should be introduced in the CRF.  
The SC is responsible for ensuring the integrity of the data introduced on CRF. However, errors 
inevitably happen during data entry, such as typographical, copying, coding or range errors. 
Typographical errors generally occur when someone is typing very fast. In the case of copying 
errors, these typically occur when the handwriting in the source document/paper CRF is not very 
legible what happens very frequently with the handwriting of doctors and really difficult the 
transcription of information. Coding errors can be made by the filling of CRF with given codes. 
Lastly, range errors happen when lower and/or upper limits of known values are exceeded when 
typing (17).   
Therefore, to assure data quality, a system must be implemented to check and query all the 
introduced data. A data query is raised when exists missing, inconsistent, or illegible data (in case 
of paper CRF), or protocol deviations on CRF. The query resolution should be as soon as possible. 
Sometimes clarification is necessary and to do so the study monitor discusses with the SC the 
pending queries (58).  
Data queries help to guarantee the quality of the data and the integrity of the study and therefore 
are an essential part of any study (58).  
During my training I worked with several types of electronic Case Report Forms (eCRF) platforms 
namely: InFormTM, RDC OnsiteTM, Medidata RaveTM, ViedocTM, BioClinica ExpressTM, among others. 
36 
I also worked with other platforms of data entry such as the QCATTM platform. This platform is 
used for a trial conducted at CIC and in it are introduced, in PDF format, the neurological scales 
applied by the psychologists to the trial participants and the respective recordings, in mp3 format, 
of the scales applied.   
Before I start working with these platforms I received training from the senior SC at CIC who 
taught me how to work with these systems and how to answer queries. 
Activities of Data Entry 
I also helped an investigator of the CIC with a database that he created and was developing. My 
help consisted in the introduction of data in the database.  
Organization, Maintenance and Update of Study Files 
Clinical studies generate vast amounts of paperwork, all of which must be stored during and after 
the studies. 
The SC has the essential role of organizing, maintaining and updating study files at the centre, 
namely the Investigator Site File (ISF), the patient’s folder and other folders specific for each 
study. Each study has its own documentation which is always very extensive and thereby is 
essential that a SC has good organizational and management skills. 
Since I already had good organizational and management skills, this task was not difficult to me.  
Control and Management of Study Supplies Stock 
The control and management of study supplies stock is one of the responsibilities of the SC. It is 
necessary to check regularly: the number of kits available at the centre and its expiry dates, the 
number of boxes available to package the samples, the number of waybills available for sending 
samples, the existence of pipettes and sleeves to process the samples, among other material. 
If there is lack of any of this material in the centre, the SC should order the necessary material 
through a specific form that is sent to the sponsor/CRO or laboratory of each clinical study (e.g., 
Covance, Quest Diagnostics, etc.).  
Preparation and Sending of the Calendar for the Next Week 
Every Friday a SC of the centre send a calendar to the pharmacy with the trial visits that will be 
performed on the next week and that need dispense of experimental medication by the 
pharmaceutical services. 
Likewise, a calendar is sent to the study nurses with the trial visits for the next week that need 
nursing support. A calendar is also sent for the psychologists when the trial visits included scales 
applied by them. 
Support to Monitoring Activities 
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The ICH/GCP guidelines, EU CT Directives and numerous national regulations demand that the 
sponsor/CRO monitor the progress of the CT at the sites where it is being conducted (49).  
The overall aim of these periodic monitoring visits is to guarantee: that the investigators and their 
staff follow the GCP, local regulations and protocol; that the rights, safety and well-being of trial 
participants are being respected and that the data reported are complete, accurate, verifiable and 
reproducible (49).  
The first monitoring visit should take place soon after the enrollment of the first few subjects in 
the trial. The next monitoring visits should be schedule based on the objective of the trial, the rate 
of enrollment and the quality of the data coming from the site (49).  
During the monitoring visits, the study monitor should meet with the investigator to review any 
issues that need clarification or explanation and to consider any questions that may appear on the 
progress of the trial (49).  
Additionally, the SC must be promptly available in these visits in order to support the study 
monitors. The SC can help through the retrieving of source documents, as required; query 
resolution and by making necessary corrections to the CRF; and by providing regulatory 
documents, as required (49).  
The Journal Club  
Every Wednesday at 8 am there is a meeting at CIC named “The Journal Club”, organized and 
presented every week by a member of the neurology group. The aim of these meetings is to 
provide additional medical and scientific knowledge to the group through the presentation of 
relevant articles in the area of neurology, namely the area of movement disorders, or video 
sessions to discuss clinical cases that are more complex and atypical than the cases of normal 
clinical practice. The SC of the centre were invited to always be present in these meetings, what 
for us it is a good opportunity to learn more about the diseases (e.g., PD) studied in the clinical 
studies conducted at the CIC. 
Meetings of the Unidade de Farmacologia Clínica  
Every two weeks on Wednesdays at 6 pm there is a meeting at UFC, with all the members of the 
UFC in which usually each sub-unit has the opportunity to share with the rest of the group their 
mission, objectives, work on a daily basis and ongoing projects. At each meeting the members of a 
sub-unit of the UFC make a presentation about the topics referred above. These meetings are a 
good way to acquire knowledge in other areas and to know the work that was being developed in 
the various sub-units. Sometimes people working in other organizations are also invited to make 
presentations. 
ALN-TTR02-003 and ALN-TTTR02-004 
During my internship at CIC I worked in almost all the clinical studies ongoing at the centre, 
helping in everything what was needed. However, in the CT ALN-TTR02-003 and ALN-TTR02-004, 
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ongoing at the CIC, I had a participation more active and autonomous, providing support to all the 
trial visits.  
The ALN-TTR02-003 is a phase 2, multicentre, open-label, extension study which aims to evaluate 
the long-term safety, clinical activity and pharmacokinetics of ALN-TTR02 (Patisiran) in patients 
with FAP who have previously received ALN-TTR02 (59).  
The ALN-TTR02-004 is a phase 3, multicentre, randomized, double-blind, placebo-controlled study 
which aims to evaluate the efficacy and safety of ALN-TTR02 (Patisiran) in patients with FAP (60).  
My participation as SC in these two studies consisted of: preparing and accompanying trial visits, 
giving support to study team, introducing data in CRF and query resolution, processing and 
shipping of laboratory samples, maintaining of study files and managing of study supplies stock. 
The study medication (ALN-TTR02) of these two trials is administered by intravenous infusion by a 
study nurse. At every trial visit a SC gives support to the study nurse in several tasks namely: 
measurement of vital signals, withdraw of blood samples and collection of urine samples, record 
of all the necessary information in the checklist (e.g., time at which vital signs were measured, 
blood samples were withdrawn, study medication was administered, etc.) and clarification on any 
questions about study procedures. 
The REGISTRY Study 
REGISTRY is a prospective OS without experimental treatment. It is a multicentre and 
multinational study and is integrated into the Huntington Project. This project is a global 
collaboration which aims to find treatments for HD (61,62).  
In OS researchers do not try to influence participants or the surroundings (63). OS draw inferences 
about the effect of an exposure or intervention on subjects, where the assignment of subjects to 
groups is observed rather than manipulated (e.g., through randomization) by the investigator 
(64). The purpose is to observe and collect data on characteristics of interest without influencing 
the participant, environment or a disease course (63). Therefore, observational research involves 
the direct observation of subjects in their natural setting (64).  
When an OS involves a medicinal product, this is prescribed in the usual manner in accordance 
with the terms of the marketing authorisation once the assignment of the patient to a particular 
therapy strategy is not influenced by a trial protocol, but by the current practice. The prescription 
of the medicinal product is also clearly separated from the decision to include the patient in the 
study and the subjects should not be submitted to any additional evaluations. The data collected 
should be analysed by epidemiological methods (31). 
Registry is sponsored by the High Q Foundation, a non-profit organization that supports various 
research projects which aim to find treatments for HD (62).  
The goals of REGISTRY are to: 
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 Collect natural history data in a large number of HD mutation carriers and subjects that 
are part of a family with the disease; 
 Relate clinical features with genetic factors, data derived from the study of body fluids 
(blood and urine) and imaging data; 
 Streamline identification and recruitment of participants for CT; 
 Plan for future research studies;  
 Develop new measures to track and/or predict HD onset and progression, along with the 
improving the existing tools (61,62).  
During my training I provided support in several activities within the framework of this study. The 
description of the activities developed is presented below. 
Conduction of Study Visits 
I provided support to some study visits and conducted a few. Since the Registry is an OS, there is 
no study medication available and therefore the study visits are easy to conduct. The Registry 
subject’s visits are only annually and at each visit there is collection of blood and urine samples; 
the participants and companions perform some self-completion questionnaires; and the 
participants are seen by a psychologist who performs some neuropsychological assessments and 
by the investigator of the study who does the clinical evaluation.  
Creation of a Study Database 
I created along with another trainee colleague a database for the study Registry. The database 
was created in Excel and comprises information about the study participants which is essential to 
a good organization and management and eases the tasks of the study.  
Site Monitoring Visit 
I had the opportunity to go to a site monitoring visit of the study REGISTRY with a SC of the centre 
who is also doing monitoring activities within the framework of this study. This SC is responsible 
for monitoring all sites in Portugal which are conducting the study because the CIC is the 
Portuguese Language Coordinator Site, in other words, the CIC is responsible by the coordination 
and monitoring of the study in Portugal.  
The visit was to the Hospital de Santo António dos Capuchos in Lisbon. 
The site monitor visit lasted one day and during the day we verified if: 
 ICF were duly signed and dated; 
 all required source documents were available on site; 
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 the information on the source documents corresponded to the information introduced 
on the CRF; 
 the information introduced in the CRF made sense and was consistent; 
 and issued queries. 
We had some limitations in this site monitor visit since sometimes it was hard to find in the 
source documents the information (e.g., medication taken by the patient) that was described on 
the CRF. 
The accompaniment of this site monitoring visit was a very enriching experience, since it allowed 
me to see in practice the role of a study monitor, the tasks carried out by the study monitor and 
how these activities are done. I also gave support to the site monitoring visit and therefore I could 
perform the tasks of a study monitor. 
Good Clinical Practices Course 
In the last day of my curricular training I attended to a GCP course. It was a one-day course and 
covered several topics, namely: introduction to the GCP and its principles; legislation and 
regulatory aspects; clinical study protocol; essential documents; responsibilities of the 
investigator, SC, monitor, CRO and sponsor; safety and adverse event reporting and practical 
aspects of conducting clinical studies. 
Any professional working in the clinical research area must have a GCP course in his/her training, 
which should be updated preferably every two years.  
Most of the topics covered in this course were already of my knowledge, but this course was 
important to assure and certify my knowledge in GCP. 
4.2. Sub-Unidade de Bioestatística e Metodologia 
I started my internship at SBM on November 11th and lasted until January 9th. Since I have a 
limited background in biostatistics and there was a person responsible for the submission of 
scientific articles and development/submission of applications for scientific projects, my 
internship was focused primarily in activities of clinical data management and medical writing. 
During these two months of internship I did some activities related to the projects that were 
ongoing in the sub-unit. 
My first activity was related with the project SENSE-PARK, a project directed towards PD. The 
team of the SBM was writing the last articles about the results of a study that had been 
conducted in the Hospital with the SENSE-PARK system and I was asked to read various articles 
about systems similar to the SENSE-PARK in order to enrich the methods, results and discussion of 
the articles that were being written.  
Currently, the assessment of the progression of PD in each patient is based on clinical 
appointments at specific time points. This approach does not reflect the real condition of patients 
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in daily life and gives only a snapshot of the disease. Therefore, to objectively measure the 
disease progression is necessary the implementation of a continuous objective measurement (65). 
This accurately measurement of the disease can result in the development of personalized 
treatment plans that will allow a better management of the disease by the patients on a daily 
basis (66).  
The SENSE-PARK project is funded under the European Community’s Seventh Framework 
Programme and aims to approach the present limitations in measuring accurately PD (65,67). The 
SENSE-PARK system consists of a set of devices that allow continuous assessment of motor 
symptoms of patients with PD on a daily basis and in their home environment. Wearable devices 
gather the information and detect fluctuation in motor symptoms. The system also includes tests 
to evaluate the non-motor symptoms (68).  
The symptoms domains that the SENSE-PARK system is capable of measure are: gait, tremor, 
balance, bradykinesia, sleep and cognitive function (68).  
My second activity was to organize and manage a clinical database obtained from the SVIG. This 
clinical database contained data characterizing ADR, reported to the INFARMED, in which the 
suspect or interacting drugs were antithrombotic drugs (anticoagulants and antiplatelet drugs). I 
also organized and managed a clinical database with data extracted from the study SENSE-PARK.  
During this internship I also had the opportunity to see clinical databases in Excel format with the 
data collected at a specific OS through the CRF and see how this information is subsequently 
validated and treated. This allowed me to know the viewpoint of the data manager and realize 
the importance and the role of each data that I introduce in the CRF as a SC.  
Lastly, I worked with a Doctor who was doing his PhD. I helped him writing an article about the 
pattern of major bleeding events in patients treated with oral anticoagulants and also gave some 
support in an article about gastrointestinal bleeding. 
Treatment with anticoagulants is associated with an increased risk of bleeding despite the proven 
benefits of this therapy in prevention/treatment of cardiovascular diseases (69). The occurrence 
of events of anticoagulant-related bleeding results in mobility, mortality and significant costs (70).   
Anticoagulant-related bleeding is a common and critical drug-induced illness (69). Thus, it is 
extremely important to determine the pattern of major bleeding events associated with 
anticoagulation treatment in order to manage and prioritize interventions to prevent this risk. 
The writing of this article allowed me to get knowledge in a new area, the area of the oral 
anticoagulants, including the traditional and new oral anticoagulants, and understand its 
limitations and associated risks.   
During my internship at the SBM I attended to an Intensive Course in Pharmacovigilance 
organized by the URFLVT and held at Hospital de Santa Maria. The topics covered in this intensive 
course were ADR mechanisms and risk factors, benefit-risk assessment, studies in 
pharmacoepidemiology, methods of drug safety monitoring, spontaneous reporting of ADR, 
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systems of imputation and causality assessment, ADR by system/organ (neuropsychiatric, 
cardiovascular, hematologic, dermatological, gastrointestinal, renal, hepatic) and ADR in 
paediatrics. 
In these two months of training at the SBM I continued providing support to the CIC whenever 
necessary. I provided support mainly in the ALN-TTR02-003 and ALN-TTTR02-004 through the 
preparation and support of subject trial visits, the processing of laboratory samples and data 
entry in CRF. 
4.3. Unidade Regional de Farmacovigilância de Lisboa e Vale do Tejo  
I started my internship at URFLVT on January 12th and finished it on 13th March. In my first two 
weeks at the Unit I read various materials essential for my integration and contextualization. 
My first activity was to read some crucial chapters, for my work at the Unit, of the book 
“Farmacovigilância em Portugal”, published by INFARMED.  
Reading this book gave me an excellent overview of: 
 the historical aspects of pharmacovigilance in a comprehensive manner; 
 the organization of the Portuguese Pharmacovigilance System; 
 the monitoring of ADR; 
 the safety periodic monitoring (management and evaluation of renewals of Marketing 
Authorizations and of Periodic Safety Update Reports (PSUR)); 
 the causality assessment; 
 medical and pharmacological terminologies (Medical Dictionary for Regulatory Activities 
(MedDRA) and Anatomical Therapeutic Chemical (ATC) classification system); 
 the main ADR that occur in each system/organ and the mechanisms involved in its 
occurrence (cardiovascular, haematological, hepatic, gastrointestinal, neuropsychiatric, 
renal, skin and respiratory ADR). 
 
I also read the applications of the Unit to the public contests, the collaboration protocols between 
the Unit and the INFARMED and the Activities Reports of the Unit of the first and second semester 
of 2014.  
Then, I read the Quality Manual which allowed me to know and understand the Quality 
Management System implemented at the Unit. The Quality Manual gave me an overview of the 
documental structure, the procedures and work instructions in force in the Unit and the 
established responsibilities. With my work at the Unit I understood the importance that a Quality 
Management System has for an institution. A Quality Management System ensures that a 
particular activity is always performed in the same way regardless of the operator and that the 
result of this activity is always the same. It is intended to prevent errors/deviations and it should 
aim continuous improvement.  
Lastly, I read the Good Pharmacovigilance Practices (GVP) giving special relevance to Module VI – 
Management and reporting of adverse reactions to medicinal products and to Module VII – 
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Periodic safety update report. The GVP provide practical measures to ease the performance of 
pharmacovigilance according to the legislation and it applies to MAH, the EMA and NCA in EU 
Member States (46).  
By reading all this material I got to know the goals, mission, vision, values and the services 
provided by the Unit and how it works. These two weeks of integration and contextualization also 
allowed the consolidation of the theoretical knowledge that I already had in the 
pharmacovigilance area and allowed the acquisition of new knowledge. 
During my training at URFLVT I attended to a conference at Faculdade de Farmácia da 
Universidade de Lisboa about “The European Medicines System” presented by Dr. Anabela Marçal 
(Head of Compliance and Inspections Department, EMA).  The themes addressed in this 
conference were: the European Medicines Regulatory System; the role of EMA and NCA; the 
marketing authorization procedures existing in the EU (centralized, mutual recognition, 
decentralized and national procedure) with special focus on the centralized evaluation system; 
the Co-ordination Group for Mutual Recognition and Decentralized Procedures – Human; the 
Common Technical Document; the marketing authorization application types (complete, generic 
medicinal products, informed consent, etc.); the appeal and referral processes and the conditional 
approval and exceptional circumstances. 
I also attended a class given by one of the pharmacists of the Unit to students of medicine at 
Hospital de Santa Maria. The class addressed themes such as the concept of generic medicine and 
bioequivalence, medicines with narrow therapeutic index, the establishment of prices of the 
generic medicines, the reference pricing system, the reimbursement in the National Health 
System and the medical prescription. 
My main activity during the internship at the URFLVT was the handling of spontaneous reports of 
ADR. This handling comprised the reception, validation, classification and processing of 
spontaneous reports of ADR.  
Additionally, I wrote case narratives, causality reports and causality letters to attach in the ADR 
Portal and also did follow-up of reports. The causality letters are also sent to the reporters.  
The process of the handling of a spontaneous report is described below.  
In pharmacovigilance, a spontaneous report concerns only one case which is constituted by a 
patient, an identifiable reporter, at least one suspected ADR and at least one suspected drug. The 
reports are received and collected in accordance with this principle (11).  
Whenever a spontaneous report is received at the URFLVT, is necessary to verify the following 
items: if the report comes from the Unit's action area, if the suspected drug is in fact a drug, if 
there is a duplicate of the concerned report, if the report has the four minimum criteria to be 
validated and what is the consistency of the report. 
For a report to be considered valid it needs to contain the following minimum information: 
 an identifiable reporter; 
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 an identifiable patient (initials or patient number and/or gender and/or age; the 
information should be as complete as possible and the patient’s name should not be 
reported); 
 at least one suspected ADR; 
 at least one suspected medicine/active substance (11).  
This minimum information is commonly called minimum criteria. It must be available for: 
 the attribution to the report of an identifying alphanumeric sequence of the SNF (the 
international number of the report); 
 the registration of the report in the SNF database; 
 the report become an available source of safety data for the generation of signals (11).  
All necessary efforts should be undertaken to obtain this minimum information (11).  
If a report does not have the minimum criteria, especially the reports about serious and/or 
unexpected ADR, it should be made attempts to obtain immediately all the required additional 
information from the reporter or from another available source (11).  
Throughout the technical and scientific evaluation of the report, namely during the causality 
assessment, it is also often necessary to contact the reporter in order to obtain additional 
information (11).  
Additionally, in certain cases it is necessary to obtain further information in relation to long-term 
consequences of the ADR (11).  
The detection of duplicates is an extremely important step. Some ADR, especially the serious 
and/or unexpected, are reported to the competent authority by more than one source (e.g., a 
physician and a pharmacist) and by more than one route (e.g., direct sending of the reporting 
form by a health professional and sending via MAH of the Council for International Organizations 
of Medical Sciences (CIOMS) model) (11).  
It is also crucial that the information on a specific spontaneous report is sufficient to enable the 
detection of duplicates. The registration of the information of each report in the database is only 
made after a duplicate detection process. This is done through the various fields of the reports, 
namely through the information regarding minimum criteria (11).  
After these steps, the report is validated. All the sheets of the report are signed and dated with 
the date of reception. Then the report is scanned and saved in the internal network of the Unit.  A 
copy of the report is printed and attached to its original.  
The Unit has seven consecutive days, counting from the day of receipt of the report, to handle the 
report and send it to the SVIG. The date on which the report should be finalized is registered in 
the online calendar of the Unit. 
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The information on the spontaneous report in the paper reporting form is then transcribed to the 
ADR Portal. The Unit has also a database in Excel format with information about all the 
spontaneous reports received at the Unit since its creation. Whenever a new spontaneous report 
is received, this database needs to be filled. 
If the spontaneous report is submitted by the reporter through the online reporting form of the 
ADR Portal, the spontaneous report is accessed by the team of the URFLVT through the back 
office of the ADR Portal and then its information is validated and printed.  
The information on the spontaneous report needs to be coded to be inserted in the ADR Portal. 
The signals and symptoms, diseases, diagnostics, therapeutic indications, research results, 
medical and surgical procedures and the family, social and medical history are codified in by the 
MedDRA. The medicines are classified by the ATC classification system (11,12).  
For all spontaneous reports (serious and non-serious), it is made a contact with the reporter, via 
e-mail or by telephone, in order to obtain or confirm data about the case and to attest that the 
reporter really exists. In reports received by telephone, this contact is only necessary when there 
is still outstanding information. The new data obtained is recorded in the printed copy of the 
report and is also added to the ADR Portal. 
After this contact with the reporter, the case narrative is written and all the information 
previously introduced in the ADR Portal, relative to that specific report, is reviewed once again by 
a second person (one of the pharmacists). This step is done within the scope of the quality system 
implemented in the Unit as a validation/ quality control step aiming to reduce the rate of errors. 
The ADR also need to be classified as “expected” or “unexpected”. This classification is performed 
based on the information presented in the SmPC, with clinical judgment whenever necessary. The 
clinical judgment is particularly necessary in the cases where the nature, intensity or evolution of 
the reported ADR differ from that described in the SmPC (11).  
“The case narrative should serve as a comprehensive, stand-alone “medical report” containing all 
known relevant clinical and related information, including patient characteristics, therapy details, 
medical history, clinical course of the event(s), diagnosis, adverse reactions and their outcomes, 
relevant laboratory evidence (including normal ranges) and any other information that supports 
or refutes the suspected adverse reactions (40, p.37).”  
It should contain, in the order listed, the following information: 
 The minimum criteria and relevant data (summary of the case); 
 Description of the onset and development of the ADR; 
 Relationship between the drug and the ADR; 
 Treatment of the ADR; 
 Other relevant data on the evaluation of the ADR; 
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 ADR evolution. 
After the finalization of the case narrative, the report is sent from the backoffice of the ADR Portal 
to the SVIG and the international number of the report is generated.  
In the follow-up of reports, the additional information should be added to the case narrative 
preceded by the date on which the information was obtained, with the reference of “follow-up”. 
The last information of the follow-up should be the evolution of the ADR, even if it is equal to the 
evolution of the initial case. 
When new information is obtained within the time frame of seven days to handle the report, this 
information is not considered a follow-up. In other words, new information is only considered as a 
follow-up when the report has already been handled and sent to the SVIG. 
The Unit has thirty days to perform the causality assessment and insert it in the database. In the 
URFLVT the causality assessment is carried out by global introspection, but other methods can be 
used (12).  
The causality assessment is performed by the physician who acts as clinical coordinator of Unit. 
However, the two pharmacists who work at the Unit also give their opinion about the causality 
assessment. 
The result of the causality assessment is expressed in degrees of probability, based on the scale of 
degrees of probability of WHO: certain; probable/likely; possible; unlikely; 
conditional/unclassified and unassessable/unclassifiable (11,12). The result is sent to the reporter 
by e-mail or post through the causality letter.  
The causality letter is a document which is intended to thank the reporter for their contribution to 
the SNF, to inform the reporter of the international number attributed to the report, to describe if 
the ADR(s) reported is/are expected or unexpected and to inform about the causality assessment 
attributed to the spontaneous report. 
Subsequently, the reports of ADR loaded in the SVIG are processed in the INFARMED through a 
phased system of receipt, validation, verification of duplications, coding and registration in 
databases, technical and scientific analysis with causality assessment and detection of problems, 
whose objective is the generation of signals (11).  
In the whole process is ensured the confidentiality of patient, reporter and MAH data (11).  
The access to reports, to the database and to results of research and analysis conducted is 
restricted. Search results to internal customers of INFARMED or external customers are always 
provided maintaining the anonymity of patients and reporters involved (11).   
The signals generated by a spontaneous reporting system provide different types of suspected 
drug safety problems. These problems include the detection of new ADR; suspicions of change of 
frequency of ADR already known; new drug interactions or new drug interactions between 
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medications and other health products or foods; quality or therapeutic inefficacy problems and 
inherent problems to the way of use of the medicine (11).  
The meticulous process of technical and scientific evaluation of reports in order to detect 
unknown security problems to date corresponds to the process of signal generation (11).  
In addition to all these activities, I also performed activities of medical writing at the Unit. I helped 
in the writing of an article to submit to a scientific journal (Pharmacoepidemiology and Drug 
Safety). The article had as a source a master’s thesis written by a physician in order to complete 
their Medical Degree. The theme of the master thesis, and therefore of the article, was the 
characterization of ADR with neuropsychiatric clinical manifestations reported spontaneously to 
the Portuguese Pharmacovigilance System in the greater Lisbon area between January, 2006 and 
December, 2012. 
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5. Discussion  
In this curricular training of ten months, I developed activities in several areas of the drug sector 
namely clinical research, pharmacovigilance, medical writing and data management. This diversity 
of activities was very important and enriching, since it allowed me to experience different areas 
and to discover my preferences and in what I would like to work in the future. Besides this, I 
gained several competences and confidence to work in any of the areas mentioned above. 
The internship at the CIC was the longest, six months, and the main focus of the entire curricular 
training. The CIC is a clinical research centre with sixteen years of experience in clinical research 
and is considered a centre of excellence in the area of neurology in Portugal. Therefore, it is the 
ideal centre to learn, grow professionally and become autonomous. The CIC has a competent, 
motivated, dedicated and proactive team of health professionals that invest the necessary time in 
the conduction of the clinical studies. This team is a key piece and a major contribution for the 
success of the centre. The CIC has qualified people working full time in the conduction of the 
clinical studies, two senior SC; the investigators of the CIC are always trying to recruit new 
patients and truly collaborate and help the SC and the whole team is in tune and works very well 
together. The CIC has also high rates of patient retention in clinical studies and low rates of 
dropouts. I believe that if there were more centres in Portugal similar to the CIC the number of 
clinical studies conducted at our country could increase and its quality could be improved. 
The SC have various responsibilities and carry out several different activities.  Additionally, in this 
centre the SC perform activities that generally are not carried out by them in other clinical 
research centres in Portugal, such as measurement of vital signs, performing ECG and processing 
of laboratory samples. Because of this particularity I liked even more of my role as SC in the CIC, 
since I could follow the entire process of the study visits since its preparation, on the day before 
the visit, until the introduction of the data in the CRF, after the study visit. 
At CIC, the SC have several activities to do every day and for different clinical studies since there is 
usually more than one study visit per day. The SC have also the responsibility of ensuring the 
rights, safety and well-being of study subjects and the credibility of clinical study data. Thus, a SC 
should have several soft skills, namely good ability to work in team, good time management, 
organizational, communication and problem-solving skills and proactivity and responsibility.  
I already had these skills since some are qualities that characterize me (e.g., good organizational 
skills and responsibility) and others were developed during my academic training (e.g., good time 
management and communication skills and proactivity). However, my internship at CIC allowed 
me to improve these skills on a daily basis. 
The description of the day by day of a SC demonstrates that these soft skills are really very 
important to do a good work as SC. Every day I had several activities to do and I had to manage 
my time and prioritize activities. I also had always many documents from different studies to fill 
in, archive or to give to the investigators to sign. It is very important do not lose any document 
and archive them in the right place to be easy to retrieve these documents whenever necessary. 
Every day things with which we are not counting happen (e.g., a patient calls and warns that 
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cannot come to the trial visit and the SC needs to cancel everything and reschedule). Thus, it is 
very important to have problem-solving skills for these unexpected situations. As SC, I also had to 
communicate with various healthcare professionals (e.g., physicians, nurses, pharmacists, 
psychologists, etc.), other professionals from the pharmaceutical companies (e.g., study monitors, 
auditors, etc.) and patients and its relatives. It is important to adapt our discourse to every type of 
person and to be clear and precise. Besides this, each person has its own personality and 
character and I had to learn to deal with it. Lastly, a SC has a position of great responsibility. Any 
error (e.g., mix the blood samples of different patients or perform a study visit out of the window) 
can compromise the patients’ well-being, the credibility of the data and/or the reputation of the 
centre. The example of mixing blood samples of different patients is a good example because 
sometimes we had two visits of the same study with different patients and I had to process all the 
blood samples in the same space and sometimes at the same time. Therefore, it was very 
important to label every tube correctly and be extremely organized and cautious. During my 
training I felt how important is to be responsible in our work and I always gave my best in 
everything I did. 
During my internship at CIC I had contact with several protocols with different study designs, 
procedures and levels of complexity; different sponsors/CRO and different neurological diseases. 
This variety was very important because it allowed me to gain a transversal knowledge in the 
clinical research in the area of neurology.  
At CIC, the SC have a constant and strong contact with the study subjects. The SC perform the 
majority of the procedures of each study visit and generally even when the SC do not perform a 
procedure (e.g., withdraw blood samples), they provide some type of support to the procedure.  
The SC are also the responsible person for guiding the patient during the visits and for explaining 
to the patient how to take the medication and how the return the medication, when it will be the 
next visit and what procedures will be necessary for the next visit. 
The major difficult that I felt at CIC was this contact with the patients of the clinical studies. The 
studies conducted at CIC have as therapeutic indication neurological diseases. The majority of 
these diseases cause high levels of morbidity and in an advanced stage, the death. Sometimes it 
was difficult to me to deal with these patients seeing its advanced stage of disease and knowing 
how its disease is going to progress. At the start, it was also difficult to make a conversation when 
I was with the patients and to create a relationship with them, but over time this process 
becomes more natural. In my opinion, I should have had a discipline at the University that had 
prepared me to deal with patients, diseases and complicated situations. Despite these difficulties, 
I consider that the contact with the patients is a very interesting and challenging part of being SC 
and with the daily practice these difficulties were successful overcome. On the other hand, it is 
very rewarding to know that we can help these patients providing them with new and innovative 
therapies. This is one of the reasons whereby I like so much of the role of SC. The clinical research 
area allows to offer new and innovative therapies to patients that have few or even any 
therapeutic options. This is exactly what happens with the majority of the neurological diseases 
that have only symptomatic treatments but no cure for the disease. 
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At the first weeks it was also difficult to manage so many activities without forgetting anything. To 
help me with so many activities I had a notebook where I wrote what I needed to do every day 
and the new things that I learnt at CIC. The CIC had also available an agenda where everything 
that was important was written. This was a very good tool of work. Over time, things have 
become more natural for me and I started to use less times my notebook. However, the agenda 
was essential to organize my day and time and I consulted it every day. The method of work 
adopted at the centre was also a good help to organize my day. The day at the CIC started always 
early, at 8 am. Generally, in the morning the study visits were conducted which included the 
clinical evaluation of the study participants, the collection and processing of biological samples, 
the request of study medication, among other procedures. At the afternoon the biological 
samples were sent to the external laboratories, the data collected at study visits were introduced 
in the eCRF, the pending queries were solved, the study visits for the next day were prepared and 
other procedures requiring more work desk were done.  
During my internship at CIC I also had the opportunity to go to a site monitoring visit. This was a 
one day experience but it was very important since it was the first contact I had with monitoring 
activities and allowed me to try new activities, such as SDV and issue of queries.  
As SC, I was not so involved in the process of implementation of the CT at the centre which 
includes the feasibility phase, qualification and site initiation visits, the submission of the CT to the 
competent authorities and discussion of the trial financial contracts. There were several reasons 
for this, namely my internship at CIC was only of six months and this period was divided in three 
months in 2014 and three months in 2015. Three months is a very short period of time to follow 
the entire implementation phase of a CT. Because of this I did not follow the entire 
implementation phase of a specific CT but I could see and follow some steps of this 
implementation phase (e.g., I was present in a SIV) in different CT.  At the CIC, the senior SC were 
responsible for the implementation phase of CT but they explained to me all the important steps 
of this process.  
It is important to highlight that my bachelor’s degree in Biomedical Sciences and my master’s 
degree in Pharmaceutical Biomedicine provided me an excellent background in the area of health 
sciences and in all phases of medicines life cycle. More important, my academic training provided 
me with important research tools. Even when I did not know something or I had doubts during 
this curricular training I knew how and where to search the information that I needed.  
My academic background was also excellent in the clinical research area and this knowledge 
facilitated my adaptation and helped me in the role of SC. However, there are things we can learn 
only in the practice (e.g., how to process and send laboratory samples) and whenever I had 
doubts or questions I always questioned the senior SC. At CIC, I had to work with several 
softwares and equipments with which I had never worked, such as the different eCRF platforms, 
ECG machines, centrifuges and even the photocopier and the fax machine. Despite this, I consider 
that my adaptation was fast and in a short period of time I became familiar with the clinical 
studies protocols, its procedures and with the dynamic of the centre. The senior SC were crucial 
for the success of my training at CIC. They explained to me everything I need to know to carry out 
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my activities as SC and were always available to answer my doubts. They were also essential for 
my successful integration in the team of the CIC. 
During my bachelor’s degree in Biomedical Sciences I studied several neurological diseases, 
namely Alzheimer’s Disease, PD, HD and FAP and this knowledge helped me to better understand 
the trials conducted at CIC. However, at the start of the training, I also had to study other diseases 
over which I had no knowledge, e.g., Multiple Sclerosis and Epilepsy.  
Regarding the research in the area of neurology there is no doubt that this is a really complex 
research area. It is well known that few drugs (on average 12%) entering CT will be approved for 
human use. In the case of central nervous system drugs the rate of successful development is 
even lower (on average 8 %) when comparing with other therapeutic areas. Besides this, half of 
these failures occur late in development (71).  
The other four months of my curricular training took place at the SBM and at the URFLVT. 
Although the main focus of my internship was the coordination of clinical studies, these four 
months at the SBM and at the URFLVT were an asset for my professional training and for this 
reason these experiences are valued throughout this report. 
The internship at the SBM allowed me to work with clinical databases and write a scientific article.  
My experience as data manager with clinical databases was short but it allowed me to see and 
understand the viewpoint of the data managers and the other side of the clinical studies. 
Additionally, I managed the clinical databases in Excel which allowed me to gain more experience 
with this programme.  
The writing of a scientific article in the cardiology area was a challenge for me.  Until this training, 
I had never written a scientific paper but I always wanted to try medical writing since it is a 
working option in the future. I also had little background in the field of oral anticoagulants and 
therefore, I had to search several articles about this topic in the PubMed and read them. In the 
end, this activity improved my writing skills and my knowledge about oral anticoagulants, 
including its advantages and risks.  
I also gave some support in an article about gastrointestinal bleeding that was successfully 
published in a scientific journal. This publication was a great pride for me and I hope the article I 
wrote has the same success.  
The internship of two months in the pharmacovigilance area was an excellent opportunity to 
know and to understand how a Regional Pharmacovigilance Unit works in practice and to carry 
out the activities undertaken daily at the Unit. It allowed me to complement my theoretical 
knowledge acquired at University and to understand much better the role and work of the 
pharmacovigilance in the assurance of the drug safety. This training also allowed me to see all the 
path of the spontaneous reports since the reporter until the NCA. The pharmacists who work at 
the URFLVT always tried to explain to me how the pharmacovigilance department works in the 
pharmaceutical industries and its connection with the work done at the Regional 
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Pharmacovigilance Units/NCA. This viewpoint is very important if I want to work in the future in 
the pharmacovigilance department of a pharmaceutical industry.  
The URFLVT has an excellent quality management system implemented and therefore each task 
performed at the Unit is described in procedures and working instructions. These documents 
helped me to perform accurately the tasks of the Unit at the first times. At URFLVT, I also had to 
work with softwares with which I had never worked, such as the ADR Portal and the dictionary 
MedDRA.  
During these two months I felt some difficulties. The first main difficulty was the codification, of 
ADR reported, with the medical dictionary MedDRA. The ADR codified and inserted in the ADR 
Portal should be as similar as possible to what the reporter wrote on the original spontaneous 
report. However, sometimes the reporter describes the ADR in a hard way to codify and 
standardize scientifically (especially reports from patients) or the exact term reported does not 
exist in the MedDRA and is necessary to find a medical synonym. With time and practice this task 
has become easier for me. The second difficulty I felt was related with the writing of the scientific 
article. The article that I wrote only could have a maximum of 3000 words to be accepted by the 
scientific journal, but the master thesis was 63 pages. Thus, it was difficult to me to select the 
important information for the article. The pharmacist at the Unit responsible for the writing of the 
article gave me an excellent help and told me the topics that I really should cover in the article 
and the topics that were not so important.  The writing of this article improved my synthesis and 
writing skills and allowed me to learn how a scientific article should be written and formatted in 
order to be published.  
During the curricular training I also had the opportunity to participate in some courses, namely 
the Intensive Course in Pharmacovigilance and the GCP Course, and in a conference and a class. 
These extra activities complemented my knowledge and enriched my resume.  
To sum up, this curricular training exceeded my expectations that were already high and 
demanding. All of my primary and secondary objectives, established before the start of the 
curricular training, were achieved with the exception of the writing of a scientific paper related to 
the area of clinical research. Although I did not achieve this specific objective, I consider that the 
other activities of medical writing performed, by me, offset this shortcoming.  
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6. Conclusion 
This curricular training allowed me to participate in various projects in three different sub-units 
(CIC, SBM and URFLVT) and to experience different work environments. Each day, during these 
ten months, was a new opportunity of learning, a new opportunity of improving my soft skills and 
a new opportunity of becoming a more complete professional. Each day was also a new challenge 
that I tried to overcome giving my best. 
This was a multidisciplinary training which enabled the establishment of a bridge between the 
academic world and the working world. It was a great experience which marked the beginning of 
my professional career and enabled my professional and personal growth. During these ten 
months I had the opportunity to work and learn with professionals that have several years of 
experience and therefore, this interaction enabled me to acquire and develop my soft skills, 
competences and working methods.  
The realization of trainings during the master’s degree is an excellent way to prepare students for 
the working world, giving them important competences and experience that are going to be 
valued by the job market. 
Regarding the role of the SC, in the internship at CIC I really understood how the work of the SC is 
crucial for the successful conduction of a CT. I cannot even imagine how CT can be conducted with 
quality and rigor without this specialized professional. The PI and other health professionals 
collaborating in the CT already have their profession (e.g., physicians, nurses, physiologists, etc.) 
and therefore do not have the availability required to manage a clinical study. Several activities of 
the CT require a lot of time, such as the introduction the data in the eCRF, the resolution of 
queries and the management of all the documentation. Additionally, over the years CT have 
become increasingly complex with the increase of procedures and bureaucracy. Thus, is crucial to 
have qualified people working full time in the conduction of the CT.  
I really like the experience as SC because at the end of the day I felt that I was contributing to 
bring new and innovative medicines to the market and help all people who suffer from 
neurological diseases. The internship at the SBM and the URFLVT enriched the curricular training, 
allowed me to experience new areas and complement my academic background and opened new 
career opportunities for me. 
This internship report aims to describe my curricular training of ten months; however I would like 
to highlight that is impossible to truly represent in a document all the work done by me and all my 
effort and commitment during this period of time. 
During the ten months of curricular training I had several activities to do, namely the daily work at 
the hospital; the exams, assignments and the writing of this report; and other extra activities. 
Sometimes it was difficult to manage my time and do so many activities but I overcome these 
difficulties, developed my time management and organizational skills and now I am a more 
proactive and autonomous person. Besides this, I achieve all the primary objectives defined at the 
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starting of the training. Regarding the secondary objectives, I only did not achieve one but I did 
other activities during the training which offset this gap.  
Finally, I would like to thank to all the members of the UFC team that invested in my professional 
formation and believed in my work and capacities, depositing their trust in it.
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